Header Logo

JORGE E CORTES

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Santellano B, Agrawal R, Duchesne G, Sharara M, Balas EA, Agrawal G, Tsai MH, Nayak-Kapoor A, Cortes JE. EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5). PMID: 38580281.
      Citations:    Fields:    
    2. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04. PMID: 38572554.
      Citations:    Fields:    
    3. Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, Okusanya OO, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. Project Confirm: Accelerated Drug Approvals for CML-Response. Clin Cancer Res. 2024 01 05; 30(1):237-238. PMID: 38178776; PMCID: PMC10783534.
      Citations:    Fields:    Translation:Humans
    4. Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, Hu A, E S, Liu M, Fang H, Wang W, Tang G, Apperley JF, Hochhaus A, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S, Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, Hu AY, E S, Liu M, Fang H, Wang W, Tang G, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S, Dewar R. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Mod Pathol. 2024 Feb; 37(2):100406. PMID: 38104892.
      Citations:    Fields:    Translation:Humans
    5. Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Br?mmendorf TH, Leip E, Viqueira A, Gambacorti-Passerini C. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica. 2023 Dec 01; 108(12):3454-3459. PMID: 37439348; PMCID: PMC10690913.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    6. Miranda-Galvis M, Tjioe KC, Balas EA, Agrawal G, Cortes JE. Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review. Blood Adv. 2023 11 14; 7(21):6466-6491. PMID: 37639318; PMCID: PMC10632659.
      Citations:    Fields:    Translation:Humans
    7. Sekeres MA, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, Mayer J, Jou E, Robak T, Taussig DC, Dombret H, Merchant A, Shaik N, O'Brien T, Roh W, Liu X, Ma W, DiRienzo CG, Chan G, Cortes JE. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023 10; 37(10):2017-2026. PMID: 37604981; PMCID: PMC10539167.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    8. Garrett M, Knight B, Cortes JE, Deininger MW. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Med. 2023 09; 12(17):17981-17992. PMID: 37553873; PMCID: PMC10524044.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    9. Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378. PMID: 37690903.
      Citations:    Fields:    Translation:Humans
    10. Sahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A, Cortes JE, Kolhe R. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers (Basel). 2023 Jun 16; 15(12). PMID: 37370824; PMCID: PMC10296552.
      Citations: 1     
    11. Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clin Cancer Res. 2023 06 13; 29(12):2179-2183. PMID: 36547666; PMCID: PMC10272032.
      Citations:    Fields:    Translation:Humans
    12. Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, G?mez-Garc?a de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023 05; 37(5):1048-1059. PMID: 36949155; PMCID: PMC10169635.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    13. Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol. 2023; 14:20406207231154708. PMID: 36845850; PMCID: PMC9943952.
      Citations: 1     
    14. Hochhaus A, R?a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garc?a-Guti?rrez V, Kapoor S, Allepuz A, Quenet S, B?doucha V, Mauro MJ. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 03; 37(3):617-626. PMID: 36717654; PMCID: PMC9991909.
      Citations: 5     Fields:    Translation:Humans
    15. Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Sasaki K, Yocolly A. Health care resource utilization in 3L?+?patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ. 2023 Jan-Dec; 26(1):915-923. PMID: 37431294.
      Citations:    Fields:    Translation:Humans
    16. Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170. PMID: 36524980.
      Citations:    Fields:    Translation:Humans
    17. Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, R?cher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2022 Nov 09. PMID: 36370742.
      Citations: 15     Fields:    
    18. Cortes JE, Lin TL, Asubonteng K, Faderl S, Lancet JE, Prebet T. Efficacy and safety of CPX-351 versus 7?+?3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022 10 26; 15(1):155. PMID: 36289532; PMCID: PMC9598030.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    19. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Godley LA, Gotlib J, Hobbs GS, Hoffman R, Jabbour EJ, Larson RA, Le Beau MM, Loh ML, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Tefferi A, Kvasnicka HM, Dombret H, Gianelli U, G?kbuget N, Hellstr?m-Lindberg E, Kiladjian JJ, L?wenberg B, Macintyre E, Thiele J, D?hner H. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228. PMID: 35767897; PMCID: PMC9479031.
      Citations:    Fields:    
    20. Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM, Cortes JE. Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk? J Clin Oncol. 2022 Nov 10; 40(32):3719-3729. PMID: 35944216.
      Citations:    
    21. Coughlin SS, Ayyala DN, Stewart JL, Cortes JE. Social needs and health-related quality of life among hematologic cancer survivors. Support Care Cancer. 2022 Nov; 30(11):8919-8925. PMID: 35895158.
      Citations:    Fields:    
    22. Breccia M, Jabbour E, Mauro M, Cortes JE, Garc?a-Guti?rrez V. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022 07 11; 15(1):90. PMID: 35818053; PMCID: PMC9272596.
      Citations:    Fields:    Translation:HumansPHPublic Health
    23. Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW, BFORE study investigators, Br?mmendorf TH, le Coutre P, Garcia-Gutierrez V, Hochhaus A. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 07; 36(7):1825-1833. PMID: 35643868; PMCID: PMC9252917.
      Citations:    Fields:    Translation:Humans
    24. Lipton JH, Gambacorti-Passerini C, Deininger MW, Cortes JE, Br?mmendorf TH, Garcia-Guti?rrez V. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022 11; 56:100968. PMID: 35570071.
      Citations:    Fields:    
    25. Takahashi N, Cortes JE, Sakaida E, Ishizawa K, Ono T, Doki N, Matsumura I, Rosti G, Ono C, Ohkura M, Tanetsugu Y, Viqueira A, Garc?a-Guti?rrez V, Br?mmendorf TH. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun; 115(6):838-851. PMID: 35235189.
      Citations:    Fields:    Translation:Humans
    26. Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Kim DDH, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Cortes JE, Aimone P, Allepuz A, Quenet S, R?a D, Abdo A, Fogliatto LM, le Coutre P, Saussele S, Garc?a-Guti?rrez V, B?doucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 11 25; 138(21):2031-2041. PMID: 34407542.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    27. Kota V, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, Leip E, Crescenzo RJ, Ferdinand R, Cortes JE, Br?mmendorf TH. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome?positive leukemias. Leuk Res. 2021 12; 111:106690. PMID: 34673442.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    28. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387. PMID: 34340254.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    29. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130. PMID: 33853292; PMCID: PMC8327731.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    30. Cortes JE, Lin TL, Uy GL, Ryan RJ, Faderl S, Lancet JE. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7?+?3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 07 13; 14(1):110. PMID: 34256819; PMCID: PMC8276472.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    31. Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491. PMID: 34171279.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    32. Heuser M, Smith BD, Fiedler W, Sekeres MA, Leber B, Merchant A, Papayannidis C, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE, Montesinos P, P?rez-Sim?n JA. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 Jul; 100(7):1917-1918. PMID: 33978823; PMCID: PMC8496603.
      Citations:    Fields:    
    33. Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94. PMID: 34130720; PMCID: PMC8204504.
      Citations: 3     Fields:    Translation:Humans
    34. Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, Ohkura M, Ono C, Viqueira A, Cortes JE, Br?mmendorf TH. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021 Jul; 114(1):65-78. PMID: 33851349.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    35. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647. PMID: 33823073.
      Citations: 4     Fields:    Translation:HumansCells
    36. Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica. 2021 04 01; 106(4):1097-1105. PMID: 33297667; PMCID: PMC8586820.
      Citations: 3     Fields:    Translation:HumansAnimals
    37. Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 03 23; 5(6):1719-1728. PMID: 33724305; PMCID: PMC7993093.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    38. Cortes JE, Kantarjian HM, Mauro MJ, An F, Nick S, Leip E, Gambacorti-Passerini C, Br?mmendorf TH. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820. PMID: 33638218.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    39. Heuser M, Smith BD, Fiedler W, Sekeres MA, Leber B, Merchant A, Papayannidis C, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G, Cortes JE, Montesinos P, P?rez-Sim?n JA. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 May; 100(5):1181-1194. PMID: 33740113; PMCID: PMC8043884.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    40. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. PMID: 32499238; PMCID: PMC7927994.
      Citations: 13     Fields:    Translation:Humans
    41. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34. PMID: 33618754; PMCID: PMC7901199.
      Citations:    Fields:    
    42. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900. PMID: 33449377.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    43. Cortes JE, Mehta P. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021 04 01; 96(4):493-507. PMID: 33368536; PMCID: PMC7986910.
      Citations: 4     Fields:    Translation:Humans
    44. Coughlin SS, Klaassen Z, Vernon M, Tingen MS, Cortes JE. Knowledge of prostate cancer among African American men: A systematic review. Prostate. 2021 02; 81(3):202-213. PMID: 33368465.
      Citations: 3     Fields:    Translation:Humans
    45. Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917. PMID: 33283580.
      Citations: 1     Fields:    Translation:Humans
    46. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134. PMID: 33681815; PMCID: PMC7935111.
      Citations: 9     Fields:    Translation:Humans
    47. Jillella AP, Cortes JE, Kota VK. Optimizing management of acute leukemia in community centers and when to refer. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):123-128. PMID: 33275676; PMCID: PMC7727530.
      Citations:    Fields:    Translation:Humans
    48. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021 02 01; 96(2):241-250. PMID: 33180322; PMCID: PMC9022629.
      Citations: 4     Fields:    Translation:Humans
    49. Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259. PMID: 33270904.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    50. Cortes JE, de Lima M, Estey EH, Giralt SA, Venditti A, Wang ES, Dombret H, Montesinos P, R?llig C. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020 10 15; 13(1):137. PMID: 33059764; PMCID: PMC7559451.
      Citations: 2     Fields:    Translation:HumansAnimals
    51. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132. PMID: 33032648; PMCID: PMC7542942.
      Citations: 7     Fields:    Translation:Humans
    52. Ganguly S, Cortes JE, Levis MJ, Martinelli G, Perl AE, Russell NH, Arunachalam M, Santos CD, Gammon G, Lesegretain A, Mires DE, Pham H, Wang Y, Khaled SK, Kr?mer A. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplant Cell Ther. 2021 02; 27(2):153-162. PMID: 33017662.
      Citations: 4     Fields:    Translation:Humans
    53. Cortes JE, Candoni A, Clark RE, Leber B, Vyas P, Zeidan AM, Heuser M, Montesinos P. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leuk Lymphoma. 2020 12; 61(14):3287-3305. PMID: 32967493.
      Citations:    Fields:    Translation:Humans
    54. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228. PMID: 32955970.
      Citations:    Fields:    Translation:HumansCells
    55. Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99. PMID: 32951163.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    56. Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RA, Kiladjian JJ. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2020 Dec; 38(5):654-664. PMID: 32592408; PMCID: PMC8895354.
      Citations: 2     Fields:    Translation:Humans
    57. Lin S, Shaik N, Chan G, Cortes JE, Ruiz-Garcia A. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. Cancer Chemother Pharmacol. 2020 10; 86(4):451-459. PMID: 32885274; PMCID: PMC7515941.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    58. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303. PMID: 32697348.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    59. Jamieson C, Martinelli G, Cortes JE, Papayannidis C. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. Blood Cancer Discov. 2020 Sep; 1(2):134-145. PMID: 34661144; PMCID: PMC8447269.
      Citations: 5     Fields:    Translation:HumansCells
    60. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134. PMID: 32557828.
      Citations: 1     Fields:    
    61. Solem CT, Bell TJ, Kwon Y, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang CJ, Cortes JE. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer. 2020 10 01; 126(19):4315-4321. PMID: 32697335; PMCID: PMC7540307.
      Citations: 2     Fields:    Translation:Humans
    62. Cortes JE, Heidel FH, Fiedler W, Smith BD, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M, Robak T, Montesinos P. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 07 14; 13(1):92. PMID: 32664995; PMCID: PMC7362563.
      Citations: 12     Fields:    Translation:Humans
    63. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700. PMID: 32561839.
      Citations: 6     Fields:    Translation:Humans
    64. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    65. Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Br?mmendorf TH. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol. 2020 May 29; 9(2):IJH26. PMID: 33005329; PMCID: PMC7510513.
      Citations: 5     
    66. Lee JH, Faderl S, Pagel JM, Jung CW, Yoon SS, Pardanani AD, Becker PS, Lee H, Choi J, Lee K, Kim M, Cortes JE. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020 05 12; 4(9):2032-2043. PMID: 32396615; PMCID: PMC7218422.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    67. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47. PMID: 32366832; PMCID: PMC7198507.
      Citations: 2     Fields:    Translation:Humans
    68. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699. PMID: 32330243; PMCID: PMC7189295.
      Citations: 1     Fields:    Translation:Humans
    69. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573. PMID: 32289808; PMCID: PMC7839068.
      Citations: 18     Fields:    Translation:Humans
    70. Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G, Hochhaus A. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 08; 34(8):2064-2073. PMID: 32265500; PMCID: PMC7387297.
      Citations: 5     Fields:    Translation:Humans
    71. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622. PMID: 32112433.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    72. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492. PMID: 32099037.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    73. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM, Nogueras-Gonz?lez GM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511. PMID: 31999839.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    74. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459. PMID: 31999850.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    75. Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Savage S, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2020 04 01; 38(10):1006-1018. PMID: 31880950; PMCID: PMC7106977.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    76. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326. PMID: 31826340; PMCID: PMC7724923.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    77. Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696. PMID: 31851157.
      Citations: 2     Fields:    Translation:Humans
    78. Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 03; 61(3):631-640. PMID: 31760835.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    79. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740. PMID: 31665578.
      Citations: 246     Fields:    Translation:HumansCTClinical Trials
    80. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395. PMID: 31595534.
      Citations: 7     Fields:    Translation:HumansCells
    81. Cortes JE, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA, Dombret H, Merchant A. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019 Nov; 15(31):3531-3545. PMID: 31516032.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    82. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961; PMCID: PMC6778960.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    83. Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol. 2019 10; 94(10):E256-E259. PMID: 31273842.
      Citations:    Fields:    Translation:HumansCells
    84. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766. PMID: 31310323.
      Citations: 10     Fields:    Translation:HumansCells
    85. Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408. PMID: 31208943; PMCID: PMC6658341.
      Citations: 14     Fields:    Translation:Humans
    86. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Hogge D, Jonas BA, Leung AY, Mehta P, Radsak M, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ, Kr?mer A, Dombret H, Montesinos P, Sica S. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 07; 20(7):984-997. PMID: 31175001.
      Citations: 112     Fields:    Translation:HumansCellsCTClinical Trials
    87. Adrianza AM, Jimenez CA, Aldana GL, Pozo L, Cortes JE, Sagar AES. Tyrosine Kinase Inhibitor-associated Fibrothorax. Am J Respir Crit Care Med. 2019 06 01; 199(11):1432. PMID: 30785770; PMCID: PMC6543723.
      Citations:    Fields:    Translation:Humans
    88. Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2019 09; 35(9):1615-1622. PMID: 30964361.
      Citations: 4     Fields:    Translation:Humans
    89. Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):509-515.e1. PMID: 31227358.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    90. Cortes JE, Gutzmer R, Kieran MW, Solomon JA. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019 Jun; 76:41-50. PMID: 31125907.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    91. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019 Jun; 76:33-40. PMID: 31108240.
      Citations: 8     Fields:    Translation:Humans
    92. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, Crescenzo R, Mamolo C, Reisman A, BFORE Study Investigators, le Coutre P, Garcia-Gutierrez V, Hochhaus A, Br?mmendorf TH. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1589-1599. PMID: 30989330.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    93. Jain P, Kantarjian H, Boddu PC, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE, Nogueras-Gonz?lez GM. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861. PMID: 30885996; PMCID: PMC6436011.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    94. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552. PMID: 30830579.
      Citations: 13     Fields:    Translation:Humans
    95. Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD. Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol. 2019; 3. PMID: 32914014; PMCID: PMC7446369.
      Citations: 1     Fields:    
    96. Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018 12 27; 11(1):143. PMID: 30587215; PMCID: PMC6307238.
      Citations: 14     Fields:    Translation:Humans
    97. Cortes JE. A second-generation TKI should always be used as initial therapy for CML. Blood Adv. 2018 12 26; 2(24):3653-3655. PMID: 30587494; PMCID: PMC6306878.
      Citations: 4     Fields:    Translation:Humans
    98. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1. PMID: 30635233.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    99. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Pollyea DA, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M, Montesinos P, DesJardins P. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389. PMID: 30555165; PMCID: PMC6365492.
      Citations: 158     Fields:    Translation:HumansCTClinical Trials
    100. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481. PMID: 30500073; PMCID: PMC6467779.
      Citations: 84     Fields:    Translation:HumansCells
    101. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. PMID: 30409776; PMCID: PMC6397669.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    102. Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL, Hehlmann R, Michallet M. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 01; 94(1):46-54. PMID: 30290003; PMCID: PMC6587733.
      Citations: 9     Fields:    Translation:Humans
    103. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469. PMID: 30318751; PMCID: PMC6246941.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    104. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961; PMCID: PMC6167965.
      Citations: 10     
    105. Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018 11; 93(11):1301-1310. PMID: 30074259; PMCID: PMC6221102.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    106. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431; PMCID: PMC6265645.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    107. Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 09 03; 8(9):88. PMID: 30190469; PMCID: PMC6127283.
      Citations: 7     Fields:    Translation:Humans
    108. Hughes TP, Laneuville P, Snyder DS, Shah NP, Paar D, Abruzzese E, Lipton JH, Cortes JE, Rousselot P, Rea D, Hochhaus A. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019 01; 104(1):93-101. PMID: 30093398; PMCID: PMC6312029.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    109. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018 08 18; 392(10147):593-606. PMID: 30078459; PMCID: PMC10230947.
      Citations: 165     Fields:    Translation:Humans
    110. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. PMID: 30071517.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    111. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692. PMID: 30024784; PMCID: PMC6127025.
      Citations: 214     Fields:    Translation:HumansCTClinical Trials
    112. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687; PMCID: PMC6039465.
      Citations: 26     Fields:    Translation:HumansCells
    113. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 08 09; 132(6):598-607. PMID: 29875101; PMCID: PMC6085992.
      Citations: 55     Fields:    Translation:HumansCellsCTClinical Trials
    114. Cortes J, Perl AE, Kantarjian H, Martinelli G, Kovacsovics T, Estey E, Strickland S, Altman JK, Burnett A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M, D?hner H, Rousselot P, Steffen B, Dombret H, Baldus CD, Kr?mer A. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 07; 19(7):889-903. PMID: 29859851; PMCID: PMC8152787.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    115. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Horst HA, Klimek VM, Cortes JE, Carella AM, Egyed M, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK, Pigneux A, R?cher C, Krug U. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518. PMID: 29794146; PMCID: PMC6278965.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    116. Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Khoury HJ, Br?mmendorf TH. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica. 2018 08; 103(8):1298-1307. PMID: 29773593; PMCID: PMC6068045.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    117. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE, Nogueras-Gonz?lez GM. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984; PMCID: PMC6226369.
      Citations: 27     Fields:    Translation:Humans
    118. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797. PMID: 29702001; PMCID: PMC6008108.
      Citations: 66     Fields:    Translation:Humans
    119. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765. PMID: 29660836; PMCID: PMC6800041.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    120. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540. PMID: 29645075.
      Citations: 8     Fields:    Translation:HumansCells
    121. Cortes JE, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM, le Coutre PD, Nicolini FE, Rea D, M?ller MC, Guilhot F. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404. PMID: 29567798; PMCID: PMC6071555.
      Citations: 119     Fields:    Translation:HumansCellsCTClinical Trials
    122. Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303. PMID: 29463550.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    123. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695. PMID: 29464484.
      Citations: 3     Fields:    Translation:Humans
    124. Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Mauro M, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O, Hehlmann R, Saussele S. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018 04; 67:67-74. PMID: 29466766; PMCID: PMC6613209.
      Citations: 7     Fields:    Translation:Humans
    125. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168. PMID: 29266206; PMCID: PMC5851790.
      Citations: 11     Fields:    Translation:Humans
    126. Gong Z, Medeiros LJ, Cortes JE, Chen Z, Zheng L, Li Y, Bai S, Lin P, Miranda RN, Jorgensen JL, McDonnell TJ, Wang W, Kantarjian HM, Hu S. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017 Dec 12; 1(26):2541-2552. PMID: 29296906; PMCID: PMC5728641.
      Citations: 13     Fields:    
    127. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):213-221. PMID: 29139135; PMCID: PMC6586071.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    128. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285. PMID: 29134664.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    129. Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30. PMID: 29152412; PMCID: PMC5679503.
      Citations: 11     
    130. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Br?mmendorf TH. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 01 20; 36(3):231-237. PMID: 29091516; PMCID: PMC5966023.
      Citations: 114     Fields:    Translation:HumansCells
    131. Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Su Y, Reisman AL, Shapiro M, Lipton JH, Br?mmendorf TH. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018 02 01; 124(3):587-595. PMID: 29072772; PMCID: PMC5813200.
      Citations: 7     Fields:    Translation:HumansCells
    132. Goldberg SL, Cortes JE, Gambacorti-Passerini C, Khoury HJ, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Lomaia E, Olavarria E, Mauro MJ, Hehlmann R, Michallet M, Hansen R. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Nov; 92(11):1214-1223. PMID: 28815757; PMCID: PMC5659133.
      Citations: 9     Fields:    Translation:Humans
    133. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091. PMID: 28835440; PMCID: PMC5680612.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    134. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402. PMID: 28743165; PMCID: PMC5673547.
      Citations: 47     Fields:    Translation:Humans
    135. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774; PMCID: PMC5727976.
      Citations: 26     Fields:    
    136. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. PMID: 28718728; PMCID: PMC5773400.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    137. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931; PMCID: PMC5739034.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    138. Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Khoury HJ, Br?mmendorf TH. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):684-695.e6. PMID: 28807791.
      Citations: 13     Fields:    Translation:HumansCells
    139. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444. PMID: 28616864; PMCID: PMC6511975.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    140. Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. Leuk Res. 2017 08; 59:65. PMID: 28575698.
      Citations: 1     Fields:    
    141. Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866. PMID: 29296729; PMCID: PMC5737601.
      Citations: 1     Fields:    
    142. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. PMID: 28295472; PMCID: PMC5828013.
      Citations: 7     Fields:    Translation:Humans
    143. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922; PMCID: PMC5544569.
      Citations: 15     Fields:    Translation:Humans
    144. Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE, Nicolini FE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 01; 123(15):2875-2880. PMID: 28387926; PMCID: PMC5573914.
      Citations: 30     Fields:    Translation:HumansCells
    145. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. PMID: 27655665; PMCID: PMC5400650.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    146. Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17. PMID: 28286924.
      Citations: 82     Fields:    Translation:Humans
    147. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. PMID: 28006851; PMCID: PMC5495018.
      Citations: 12     Fields:    Translation:HumansCells
    148. Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528. PMID: 27927766; PMCID: PMC5394958.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    149. DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):348-355. PMID: 27913501; PMCID: PMC6142505.
      Citations: 44     Fields:    Translation:Humans
    150. Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, Huang X, Babu KG, Abdulkadyrov K, Shen ZX, Liang Z, Owugah T, Szczudlo T, Khanna S, Fellague-Chebra R, de Oliveira JSR, Sacha T, Bendit I, le Coutre PD. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591. PMID: 27890073.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    151. Cortes JE, Hochhaus A. Reply to K.R. Hoffman. J Clin Oncol. 2017 02 10; 35(5):567-568. PMID: 29236618.
      Citations:    Fields:    Translation:Humans
    152. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. PMID: 27763690; PMCID: PMC5293656.
      Citations:    Fields:    Translation:Humans
    153. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467. PMID: 27696391; PMCID: PMC5321542.
      Citations: 18     Fields:    Translation:Humans
    154. Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016 11; 50:123-131. PMID: 27736729.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    155. Maiti A, Cortes JE, Brown YD, Kantarjian HM. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma. 2017 03; 58(3):722-725. PMID: 27658536; PMCID: PMC5250544.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    156. Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymphoma Myeloma Leuk. 2017 02; 17(2):78-82. PMID: 28082112.
      Citations: 30     Fields:    Translation:Humans
    157. Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Gambacorti-Passerini C, Br?mmendorf TH. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 12; 91(12):1206-1214. PMID: 27531525; PMCID: PMC5303616.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    158. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. PMID: 27602508; PMCID: PMC5321541.
      Citations: 29     Fields:    Translation:HumansCells
    159. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. PMID: 27508525; PMCID: PMC5321530.
      Citations: 7     Fields:    Translation:HumansCells
    160. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343. PMID: 27509035; PMCID: PMC5073019.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    161. Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S86-92. PMID: 27521332; PMCID: PMC5843379.
      Citations: 2     Fields:    Translation:Humans
    162. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. PMID: 27479888; PMCID: PMC5321539.
      Citations: 51     Fields:    Translation:HumansCellsCTClinical Trials
    163. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 09; 48:84-91. PMID: 27505637.
      Citations: 45     Fields:    Translation:Humans
    164. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. PMID: 27178680; PMCID: PMC5558853.
      Citations: 36     Fields:    Translation:HumansCells
    165. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5. PMID: 27169385; PMCID: PMC4946992.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    166. Shah NP, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Saglio G, Rousselot P, Hochhaus A. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74. PMID: 27192969; PMCID: PMC5094534.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    167. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66. PMID: 27244347; PMCID: PMC5014667.
      Citations: 30     Fields:    Translation:Humans
    168. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7. PMID: 27235138; PMCID: PMC4965905.
      Citations: 63     Fields:    Translation:HumansCells
    169. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu? C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na?ve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 07 10; 34(20):2333-40. PMID: 27217448; PMCID: PMC5118045.
      Citations: 243     Fields:    Translation:HumansCTClinical Trials
    170. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7. PMID: 27175025; PMCID: PMC4967581.
      Citations: 2     Fields:    Translation:Humans
    171. Whiteley J, Reisman A, Shapiro M, Cortes J, Cella D. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016 08; 32(8):1325-34. PMID: 27045164.
      Citations: 12     Fields:    Translation:Humans
    172. Cortes JE, Jean Khoury H, Kantarjian H, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C, Br?mmendorf TH. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016 06; 91(6):606-16. PMID: 26971533; PMCID: PMC5548463.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    173. Lipton JH, Chuah C, Rosti G, Simpson D, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators, Guerci-Bresler A, Assouline S, Etienne G, Nicolini FE, le Coutre P, Guilhot F, Hochhaus A. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21. PMID: 27083332.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    174. Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873. PMID: 27054578; PMCID: PMC5650058.
      Citations: 9     Fields:    Translation:HumansCells
    175. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 06 02; 127(22):2742-50. PMID: 27006386; PMCID: PMC4915795.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    176. Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407. PMID: 26998677; PMCID: PMC5071708.
      Citations: 21     Fields:    Translation:HumansCells
    177. Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk. 2016 05; 16(5):286-96. PMID: 26993758; PMCID: PMC4965237.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    178. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008; PMCID: PMC5834229.
      Citations:    Fields:    Translation:Humans
    179. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98. PMID: 26603259; PMCID: PMC4818660.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    180. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hughes TP, Rivera VM, Branford S, M?ller MC, Hochhaus A. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12. PMID: 26603839; PMCID: PMC4760131.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    181. Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH, Br?mmendorf TH. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan; 172(1):97-110. PMID: 26537529; PMCID: PMC4737299.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    182. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205; PMCID: PMC4826052.
      Citations: 38     Fields:    Translation:Humans
    183. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. PMID: 26479889; PMCID: PMC4707980.
      Citations: 16     Fields:    Translation:Humans
    184. Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015 Dec; 90(12):1111-5. PMID: 26348106; PMCID: PMC5115878.
      Citations: 36     Fields:    Translation:Humans
    185. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc. 2015 Oct; 90(10):1440-54. PMID: 26434969; PMCID: PMC5656269.
      Citations: 23     Fields:    Translation:HumansCells
    186. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9. PMID: 25904378; PMCID: PMC4712116.
      Citations: 14     Fields:    Translation:Humans
    187. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70. PMID: 26299958; PMCID: PMC4618182.
      Citations: 10     Fields:    Translation:Humans
    188. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885; PMCID: PMC4666803.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    189. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 01; 126(14):1699-706. PMID: 26243778; PMCID: PMC4624442.
      Citations: 17     Fields:    Translation:HumansCells
    190. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A, Masszi T. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1(5):643-51. PMID: 26181658.
      Citations: 141     Fields:    Translation:HumansCTClinical Trials
    191. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Horst HA, Klimek VM, Cortes J, Roboz GJ, Odenike O, Havelange V, Maertens J, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM, Pigneux A, Recher C, Thomas X, Derigs HG. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036. PMID: 26234174; PMCID: PMC4822512.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    192. Yilmaz M, Lahoti A, O'Brien S, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE, Nogueras-Gonz?lez GM. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904. PMID: 26217876; PMCID: PMC4519988.
      Citations: 21     Fields:    Translation:Humans
    193. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73. PMID: 26017166; PMCID: PMC4546505.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    194. Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015 Aug; 2(8):e339-46. PMID: 26688487.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    195. Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7. PMID: 26205361; PMCID: PMC4770883.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    196. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600; PMCID: PMC5365030.
      Citations: 44     Fields:    Translation:Humans
    197. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7. PMID: 26124496; PMCID: PMC4528066.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    198. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6. PMID: 26183878; PMCID: PMC4546869.
      Citations: 21     Fields:    Translation:Humans
    199. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62. PMID: 26141213; PMCID: PMC4837956.
      Citations: 4     Fields:    Translation:HumansCells
    200. Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015 Jul; 26(7):1440-6. PMID: 26041765; PMCID: PMC4855240.
      Citations: 28     Fields:    Translation:Humans
    201. Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32. PMID: 26031918; PMCID: PMC4497963.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    202. Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE, Br?mmendorf TH. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep; 90(9):755-68. PMID: 26040495; PMCID: PMC5132035.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    203. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3. PMID: 25999449.
      Citations: 7     Fields:    Translation:Humans
    204. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7. PMID: 26012362; PMCID: PMC4547830.
      Citations: 8     Fields:    Translation:HumansCells
    205. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93. PMID: 26688093; PMCID: PMC4884053.
      Citations: 86     Fields:    Translation:Humans
    206. Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904. PMID: 25887498; PMCID: PMC4486224.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    207. Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32. PMID: 25888368; PMCID: PMC4396174.
      Citations: 12     Fields:    Translation:HumansCells
    208. Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R, Card?-Vila M. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 01; 21(13):3041-51. PMID: 25779950; PMCID: PMC4490100.
      Citations: 4     Fields:    Translation:HumansCells
    209. Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73. PMID: 25764322.
      Citations: 6     Fields:    Translation:Humans
    210. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3. PMID: 25716073; PMCID: PMC4977576.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    211. Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2. PMID: 25795639; PMCID: PMC4509631.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    212. Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015 Jul; 56(7):2092-7. PMID: 25641433; PMCID: PMC4919663.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    213. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015 Apr; 122(2):391-8. PMID: 25666482; PMCID: PMC4369460.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    214. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597. PMID: 25654108; PMCID: PMC4310492.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    215. Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE, Guerci-Bresler A. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44. PMID: 25586015; PMCID: PMC5650096.
      Citations: 25     Fields:    Translation:Humans
    216. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20. PMID: 26687423; PMCID: PMC4936479.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    217. DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015 Jan; 16(1):95-106. PMID: 25480777.
      Citations: 10     Fields:    Translation:Humans
    218. Verstovsek S, Hoffman R, Mascarenhas J, McCoon P, Tang W, Cortes J, Kantarjian H, Soria JC, Bahleda R, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. 2015 Feb; 39(2):157-63. PMID: 25530567.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    219. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4. PMID: 25368968; PMCID: PMC4447180.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    220. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61. PMID: 25336333; PMCID: PMC4320000.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    221. Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015 Jan; 90(1):27-30. PMID: 25251041; PMCID: PMC4276516.
      Citations: 17     Fields:    Translation:Humans
    222. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53. PMID: 25312977; PMCID: PMC4323735.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    223. Agarwal A, Mackenzie RJ, Jeng S, Carey A, LaTocha DH, Fleischman AG, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW, Besson A, Duquesnes N. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 2014 Nov 20; 124(22):3260-73. PMID: 25293778; PMCID: PMC4239335.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    224. Kantarjian H, O'Brien S, Jabbour E, Barnes G, Pathak A, Cortes J. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21. PMID: 25458084.
      Citations: 12     Fields:    Translation:Humans
    225. Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74. PMID: 25281355; PMCID: PMC4197326.
      Citations: 36     Fields:    Translation:Humans
    226. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64. PMID: 25281606; PMCID: PMC4231417.
      Citations: 37     Fields:    Translation:Humans
    227. Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014 Sep 20; 32(27):3077. PMID: 25002733.
      Citations: 5     Fields:    Translation:Humans
    228. Kadia TM, Ravandi F, O'Brien S, Cortes J, Kantarjian HM. Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):139-51. PMID: 25441110; PMCID: PMC4344862.
      Citations: 21     Fields:    Translation:Humans
    229. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6. PMID: 25441108; PMCID: PMC4344906.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    230. Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15; 121(2):234-42. PMID: 25223583; PMCID: PMC5542857.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    231. Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014; 132(3-4):298-306. PMID: 25228555.
      Citations: 6     Fields:    Translation:Humans
    232. Cortes JE, Guilhot F, Pavlov D, Countouriotis AM, Gambacorti-Passerini C, Br?mmendorf TH, de Souza CA, Duvilli? L, Gogat K. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan; 168(1):69-81. PMID: 25196702; PMCID: PMC4274978.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    233. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6. PMID: 25217891; PMCID: PMC4182146.
      Citations: 1     Fields:    Translation:HumansCells
    234. Zabriskie MS, Eide CA, Tantravahi SK, Estrada J, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Druker BJ, Deininger MW, O'Hare T, Vellore NA, Nicolini FE, Hern?ndez-Boluda JC, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Baron R. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442. PMID: 25132497; PMCID: PMC4160372.
      Citations: 131     Fields:    Translation:HumansCells
    235. Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Khattry N, Kantarjian HM, Duvilli? L, Br?mmendorf TH. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct; 89(10):947-53. PMID: 24944159; PMCID: PMC4305212.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    236. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8. PMID: 24990142; PMCID: PMC4431614.
      Citations: 19     Fields:    Translation:Humans
    237. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4. PMID: 24844364; PMCID: PMC4297591.
      Citations: 2     Fields:    Translation:Humans
    238. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398; PMCID: PMC4239168.
      Citations: 29     Fields:    Translation:Humans
    239. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9. PMID: 25047979; PMCID: PMC4157096.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    240. DiNardo CD, Tang G, Pemmaraju N, Wang SA, Pike A, Garcia-Manero G, Cortes J, Bueso-Ramos C, Kantarjian HM. Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):47-51. PMID: 25081372; PMCID: PMC4849878.
      Citations: 4     Fields:    Translation:HumansCells
    241. Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74. PMID: 24942980; PMCID: PMC4146738.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    242. Romo CG, Jain P, Cortes JE. Numb chin syndrome by precursor B acute lymphoblastic leukemia. Am J Hematol. 2014 Aug; 89(8):860-1. PMID: 24850438.
      Citations: 3     Fields:    Translation:Humans
    243. Mathisen MS, Kantarjian HM, Cortes J, Jabbour EJ. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87. PMID: 24984571.
      Citations: 12     Fields:    Translation:Humans
    244. Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8. PMID: 24880021; PMCID: PMC4174349.
      Citations: 7     Fields:    Translation:Humans
    245. Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10. PMID: 24875590; PMCID: PMC4167474.
      Citations: 21     Fields:    Translation:Humans
    246. Gambacorti-Passerini C, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE, Br?mmendorf TH. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul; 89(7):732-42. PMID: 24711212; PMCID: PMC4173127.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    247. Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32. PMID: 24777602; PMCID: PMC4054323.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    248. Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54. PMID: 24749672; PMCID: PMC4109297.
      Citations: 16     Fields:    Translation:HumansAnimals
    249. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. PMID: 24737502; PMCID: PMC4124083.
      Citations: 58     Fields:    Translation:Humans
    250. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22; 123(21):3239-46. PMID: 24687088; PMCID: PMC4624448.
      Citations: 120     Fields:    Translation:HumansCTClinical Trials
    251. Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74. PMID: 24619500; PMCID: PMC4073635.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    252. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8. PMID: 24375514; PMCID: PMC4140180.
      Citations: 15     Fields:    Translation:HumansCells
    253. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7. PMID: 24779033; PMCID: PMC4196860.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    254. Shah NP, Cortes JE, Schiffer CA, le Coutre P, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G, Guilhot F, Br?mmendorf TH. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24. PMID: 24569263; PMCID: PMC4915794.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    255. Cortes JE, Talpaz M, Kantarjian H. Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2014 02 06; 370(6):577. PMID: 24499221.
      Citations: 7     Fields:    Translation:Humans
    256. Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40. PMID: 24501394; PMCID: PMC4048124.
      Citations: 43     Fields:    Translation:HumansCells
    257. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9. PMID: 24138309; PMCID: PMC4139917.
      Citations: 26     Fields:    Translation:Humans
    258. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71. PMID: 24461514; PMCID: PMC4167660.
      Citations: 5     Fields:    Translation:HumansCells
    259. Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J, Quint?s-Cardama A. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8. PMID: 24594142; PMCID: PMC4099320.
      Citations: 6     Fields:    Translation:Humans
    260. Anzalone CL, Cohen PR, Kurzrock R, Cortes JE. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J. 2014 Jan 15; 20(1):21242. PMID: 24456946.
      Citations:    Fields:    Translation:Humans
    261. Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol. 2014; 99(5):616-24. PMID: 24658916.
      Citations: 17     Fields:    Translation:Humans
    262. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C, Br?mmendorf TH. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27; 123(9):1309-18. PMID: 24345751; PMCID: PMC4467890.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    263. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8. PMID: 24440659; PMCID: PMC4182922.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    264. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG, D?hner H, M?schen M. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75. PMID: 24346116; PMCID: PMC3975047.
      Citations: 288     Fields:    Translation:HumansAnimalsCells
    265. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. PMID: 24374145; PMCID: PMC4414320.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    266. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. PMID: 24332214; PMCID: PMC3959284.
      Citations: 15     Fields:    Translation:Humans
    267. DiNardo CD, Cortes JE. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Feb; 23(2):265-72. PMID: 24313331.
      Citations: 4     Fields:    Translation:HumansAnimals
    268. Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortes J, Maziarz RT, Gale RP, Saber W. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4. PMID: 24321745; PMCID: PMC4026353.
      Citations: 8     Fields:    Translation:Humans
    269. Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Arch Pathol Lab Med. 2014 Sep; 138(9):1186-92. PMID: 24308645.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    270. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Chuah C, Pavlovsky C, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A, Boqu? C, Mayer J. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500. PMID: 24311723; PMCID: PMC4190618.
      Citations: 146     Fields:    Translation:HumansCTClinical Trials
    271. Williams LA, Yucel E, Cortes JE, Cleeland CS. Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clin Investig (Lond). 2013 Dec 01; 3(12):1127-1138. PMID: 24910769; PMCID: PMC4043382.
      Citations: 1     
    272. Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52. PMID: 24236822; PMCID: PMC4181370.
      Citations: 13     Fields:    Translation:Humans
    273. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8. PMID: 24270737; PMCID: PMC4032802.
      Citations: 274     Fields:    Translation:HumansCells
    274. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7. PMID: 24447728; PMCID: PMC4098769.
      Citations: 6     Fields:    Translation:HumansCells
    275. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30. PMID: 24355079; PMCID: PMC4096861.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    276. Jain P, Romo CG, Khoury HJ, Kantarjian H, Cortes J. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica. 2013 Nov; 98(11):e141-2. PMID: 24186316; PMCID: PMC3815188.
      Citations: 1     Fields:    Translation:HumansCells
    277. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4. PMID: 24033106; PMCID: PMC4105975.
      Citations: 2     Fields:    Translation:HumansCells
    278. Karjalainen K, Pasqualini R, Cortes JE, Kornblau SM, Lichtiger B, O'Brien S, Kantarjian HM, Sidman RL, Arap W, Koivunen E. Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia. Cancer. 2014 Feb 15; 120(4):589-602. PMID: 24496871; PMCID: PMC4457455.
      Citations:    Fields:    Translation:Humans
    279. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5. PMID: 24157581.
      Citations: 19     Fields:    Translation:Humans
    280. Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One. 2013; 8(10):e78453. PMID: 24223100; PMCID: PMC3816767.
      Citations: 22     Fields:    Translation:HumansCells
    281. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97. PMID: 24161923; PMCID: PMC3886623.
      Citations: 49     Fields:    Translation:Humans
    282. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013 Oct 22; 6:79. PMID: 24283870; PMCID: PMC4222119.
      Citations: 21     Fields:    Translation:Humans
    283. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80. PMID: 24151050; PMCID: PMC3946911.
      Citations: 17     Fields:    Translation:Humans
    284. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73. PMID: 24142997; PMCID: PMC3943309.
      Citations: 77     Fields:    Translation:Humans
    285. Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi F. Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e47-9. PMID: 24128595; PMCID: PMC4103408.
      Citations: 7     Fields:    Translation:Humans
    286. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44. PMID: 24004182; PMCID: PMC4143910.
      Citations: 16     Fields:    Translation:Humans
    287. Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83. PMID: 24246694; PMCID: PMC4098770.
      Citations: 13     Fields:    Translation:Humans
    288. Nazha A, Romo CG, Kantarjian H, Cortes J. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica. 2013 Oct; 98(10):e131. PMID: 24091930; PMCID: PMC3789475.
      Citations: 6     Fields:    Translation:HumansCells
    289. Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, Ost DE. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013 Oct; 10(5):432-40. PMID: 23987587; PMCID: PMC3960911.
      Citations: 30     Fields:    Translation:Humans
    290. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6. PMID: 24068492; PMCID: PMC3952679.
      Citations: 8     Fields:    Translation:Humans
    291. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70. PMID: 24065243; PMCID: PMC3854108.
      Citations: 56     Fields:    Translation:Humans
    292. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9. PMID: 24060289; PMCID: PMC3835390.
      Citations: 4     Fields:    Translation:Humans
    293. Grgurevic S, Rozovski U, Li P, Estrov Z, Cortes J, Quint?s-Cardama A. Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):681-5. PMID: 24060288; PMCID: PMC4162086.
      Citations:    Fields:    Translation:HumansCells
    294. Falchi L, Kantarjian HM, Wang X, Verma D, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE, Quint?s-Cardama A. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852; PMCID: PMC3849405.
      Citations: 28     Fields:    Translation:Humans
    295. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86. PMID: 23927391; PMCID: PMC4127158.
      Citations: 13     Fields:    Translation:Humans
    296. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926; PMCID: PMC4110914.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    297. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57. PMID: 23999433; PMCID: PMC3784537.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    298. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10; 31(29):3681-7. PMID: 24002496; PMCID: PMC3804291.
      Citations: 159     Fields:    Translation:HumansCellsCTClinical Trials
    299. Chakhachiro ZI, Zuo Z, Aladily TN, Kantarjian HM, Cortes JE, Alayed K, Nguyen MH, Medeiros LJ, Bueso-Ramos C. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol. 2013 Sep; 140(3):370-8. PMID: 23955456.
      Citations: 6     Fields:    Translation:Humans
    300. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94. PMID: 23969308; PMCID: PMC4120258.
      Citations: 1     Fields:    Translation:Humans
    301. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81. PMID: 23969309; PMCID: PMC4101888.
      Citations: 3     Fields:    Translation:Humans
    302. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6. PMID: 23993426; PMCID: PMC3818458.
      Citations: 2     Fields:    Translation:Humans
    303. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar; 55(3):624-7. PMID: 23937105; PMCID: PMC4188389.
      Citations: 12     Fields:    Translation:Humans
    304. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920. PMID: 23896412; PMCID: PMC3798995.
      Citations: 17     Fields:    Translation:Humans
    305. Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29. PMID: 23890944; PMCID: PMC4160831.
      Citations: 34     Fields:    Translation:Humans
    306. Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15; 73(18):5775-86. PMID: 23887971; PMCID: PMC3894913.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    307. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4. PMID: 23890523; PMCID: PMC4232180.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    308. Nazha A, Kantarjian H, Cortes J, Quint?s-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013 Oct; 14(14):1977-86. PMID: 23875628.
      Citations: 4     Fields:    Translation:HumansAnimals
    309. Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013 Sep 12; 122(11):1974-82. PMID: 23847196; PMCID: PMC3772501.
      Citations: 31     Fields:    Translation:Humans
    310. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561; PMCID: PMC3976223.
      Citations: 77     Fields:    Translation:HumansCells
    311. Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2013 Oct; 163(1):130-2. PMID: 23829510; PMCID: PMC4128010.
      Citations:    Fields:    Translation:HumansCells
    312. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8. PMID: 23812943; PMCID: PMC3815167.
      Citations: 8     Fields:    Translation:Humans
    313. Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Martinelli G, Mayer J, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Baccarani M, Guilhot F, Mahon FX, M?ller MC, Sau?ele S, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84. PMID: 23803709; PMCID: PMC4915804.
      Citations: 652     Fields:    Translation:Humans
    314. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6. PMID: 23790798; PMCID: PMC4120256.
      Citations: 2     Fields:    Translation:Humans
    315. Kantarjian HM, O'Brien S, Cortes J. Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):530-3. PMID: 23790799; PMCID: PMC3775965.
      Citations: 36     Fields:    Translation:Humans
    316. Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S, Quint?s-Cardama A. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901. PMID: 23782935; PMCID: PMC3739035.
      Citations: 87     Fields:    Translation:HumansCTClinical Trials
    317. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7. PMID: 23777764; PMCID: PMC3731927.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    318. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):584-91. PMID: 23787123; PMCID: PMC3775895.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    319. Alayed K, Medeiros LJ, Schultz RA, Cortes J, Lu G, Bueso-Ramos CE, Konoplev S. Value of oligonucleotide-based array comparative genomic hybridization for diagnosis of acute promyelocytic leukemia in a patient negative for t(15;17)(q24.1;q21.2)/promyelocytic leukemia-retinoic acid receptor, alpha by conventional cytogenetics and fluorescence in situ hybridization. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):507-10. PMID: 23770155; PMCID: PMC4259115.
      Citations:    Fields:    Translation:Humans
    320. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84. PMID: 23770156; PMCID: PMC3752280.
      Citations: 9     Fields:    Translation:Humans
    321. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):485-92. PMID: 23769669; PMCID: PMC4112369.
      Citations: 11     Fields:    Translation:Humans
    322. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014 Feb; 28(2):289-92. PMID: 23760400; PMCID: PMC4457325.
      Citations: 56     Fields:    Translation:Humans
    323. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quint?s-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40. PMID: 23763915; PMCID: PMC4114766.
      Citations: 12     Fields:    Translation:Humans
    324. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83. PMID: 23763918; PMCID: PMC4341913.
      Citations:    Fields:    Translation:Humans
    325. Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul; 98(7):e78-9. PMID: 23753022; PMCID: PMC3696599.
      Citations: 11     Fields:    Translation:Humans
    326. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      Citations: 25     Fields:    Translation:Humans
    327. Cortes JE. A journey searching for a cure for leukemia. Interviewed by Natasha Galukande. Future Oncol. 2013 Jun; 9(6):785-7. PMID: 23718297.
      Citations:    Fields:    Translation:Humans
    328. Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol. 2013 Jun; 14(2):127-43. PMID: 23572291.
      Citations: 16     Fields:    Translation:Humans
    329. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Hochhaus A, Dufva IH, Kim DW, Cortes J, Mauro MJ, Chuah C, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Michallet M, Goldman J, Apperley JF, Marin D, Etienne G, M?ller MC, Labussi?re H, Morisset S, Maguer-Satta V, Mahon FX. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013 Oct; 98(10):1510-6. PMID: 23716543; PMCID: PMC3789454.
      Citations: 24     Fields:    Translation:Humans
    330. Lu G, Schulz RA, Bueso-Ramos CE, Cortes JE, Iris Wang X, Medeiros LJ, Yin CC. Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia. J Clin Pathol. 2013 Sep; 66(9):826-9. PMID: 23703854.
      Citations:    Fields:    Translation:Humans
    331. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013 Aug; 162(4):548-52. PMID: 23691988; PMCID: PMC3866040.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    332. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7. PMID: 23573823; PMCID: PMC3874259.
      Citations: 14     Fields:    Translation:Humans
    333. Ravandi F, Cortes J, Kantarjian H. Is there a standard induction regimen for patients with AML? Lancet Oncol. 2013 Jun; 14(7):565-6. PMID: 23664706; PMCID: PMC4111562.
      Citations:    Fields:    Translation:Humans
    334. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36. PMID: 23633004; PMCID: PMC3720844.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    335. Farroni JS, Zwelling L, Cortes J, Kantarjian H. Saving Medicare through patient-centered changes--the case of injectables. N Engl J Med. 2013 Apr 25; 368(17):1572-3. PMID: 23614583.
      Citations: 1     Fields:    Translation:Humans
    336. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Cortes J, Quint?s-Cardama A. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74. PMID: 23620574; PMCID: PMC3743466.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    337. Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1599-607. PMID: 23609479; PMCID: PMC3668123.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    338. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62. PMID: 23613521; PMCID: PMC3674666.
      Citations: 158     Fields:    Translation:HumansCellsCTClinical Trials
    339. Mouhayar E, Durand JB, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf. 2013 Sep; 12(5):687-96. PMID: 23560546.
      Citations: 9     Fields:    Translation:Humans
    340. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666. PMID: 23530930; PMCID: PMC4068703.
      Citations: 11     Fields:    Translation:HumansCells
    341. Al-Kali A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829; PMCID: PMC4089101.
      Citations: 13     Fields:    Translation:Humans
    342. Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM, Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May; 88(5):350-4. PMID: 23468307; PMCID: PMC5558840.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    343. Cortes J, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M, Kantarjian H. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013 Apr; 14(4):354-62. PMID: 23453583; PMCID: PMC5557006.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    344. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9. PMID: 23343175; PMCID: PMC4135587.
      Citations: 6     Fields:    Translation:Humans
    345. Kantarjian H, Pierce S, Cortes J, Verstovsek S, Quint?s-Cardama A. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):315-318.e2. PMID: 23391717; PMCID: PMC3901422.
      Citations: 10     Fields:    Translation:Humans
    346. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 01; 133(3):534-43. PMID: 23280377; PMCID: PMC3904286.
      Citations: 20     Fields:    Translation:Humans
    347. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013 May; 37(5):552-5. PMID: 23391517; PMCID: PMC4408989.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    348. Sever M, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma. 2013 Sep; 54(9):1959-64. PMID: 23278641; PMCID: PMC5127201.
      Citations: 3     Fields:    Translation:HumansCells
    349. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6. PMID: 23318257; PMCID: PMC4160838.
      Citations: 4     Fields:    Translation:Humans
    350. Zheng W, Medeiros LJ, Hu Y, Powers L, Cortes JE, Ravandi-Kashani F, Kantarjian HH, Wang SA. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):307-14. PMID: 23313069; PMCID: PMC4188388.
      Citations: 7     Fields:    Translation:Humans
    351. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quint?s-Cardama A. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43. PMID: 23276886; PMCID: PMC4114759.
      Citations:    Fields:    Translation:Humans
    352. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5. PMID: 23265768; PMCID: PMC3860181.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    353. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8. PMID: 23260600; PMCID: PMC4098775.
      Citations: 6     Fields:    Translation:Humans
    354. Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):153-8. PMID: 23266036; PMCID: PMC3854973.
      Citations: 8     Fields:    Translation:Humans
    355. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):342-6. PMID: 23246163; PMCID: PMC4019340.
      Citations: 2     Fields:    Translation:HumansCells
    356. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013 Jul; 54(7):1411-7. PMID: 23121646; PMCID: PMC5525971.
      Citations: 39     Fields:    Translation:Humans
    357. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88. PMID: 23190221; PMCID: PMC3777383.
      Citations: 272     Fields:    Translation:HumansCTClinical Trials
    358. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42. PMID: 23135353; PMCID: PMC4181539.
      Citations: 22     Fields:    Translation:HumansCells
    359. Cortes J. CML: the good, the better, and the difficult choices. Blood. 2012 Nov 08; 120(19):3866-7. PMID: 23144157.
      Citations: 1     Fields:    Translation:Humans
    360. Talpaz M, Hehlmann R, Mercer J, Cortes J, Quint?s-Cardama A. Re-emergence of interferon-a in the treatment of chronic myeloid leukemia. Leukemia. 2013 Apr; 27(4):803-12. PMID: 23238589; PMCID: PMC3703612.
      Citations: 58     Fields:    Translation:Humans
    361. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13. PMID: 23174881; PMCID: PMC4140185.
      Citations: 7     Fields:    Translation:Humans
    362. Zhou Y, Jorgensen JL, Wang SA, Ravandi F, Cortes J, Kantarjian HM, Medeiros LJ, Konoplev S. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012 Nov; 138(5):744-50. PMID: 23086776.
      Citations: 6     Fields:    Translation:Humans
    363. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):287-91. PMID: 23123105; PMCID: PMC4445419.
      Citations: 13     Fields:    Translation:Humans
    364. Cortes J. Bosutinib in the treatment of chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012 Nov; 10(11):736-7. PMID: 23271260.
      Citations: 1     Fields:    Translation:Humans
    365. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9. PMID: 23115106; PMCID: PMC4085099.
      Citations: 31     Fields:    Translation:HumansCells
    366. Kantarjian HM, Larson RA, Deering KL, Mauro MJ, Cort?s JE. Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54. PMID: 23103085; PMCID: PMC3645375.
      Citations: 3     Fields:    Translation:Humans
    367. Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3. PMID: 23086624; PMCID: PMC4195445.
      Citations: 8     Fields:    Translation:Humans
    368. Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H, Quint?s-Cardama A. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5. PMID: 23071272; PMCID: PMC3952725.
      Citations: 81     Fields:    Translation:HumansCells
    369. Cortes J, Radich J, Mauro MJ. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012 Oct; 10(10 Suppl 19):1-16. PMID: 23187745.
      Citations: 1     Fields:    Translation:Humans
    370. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012 Oct 01; 10 Suppl 3:S1-S13. PMID: 23055247.
      Citations: 20     Fields:    Translation:Humans
    371. Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Estrov Z, Pemmaraju N, Cort?s JE. Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):93-6. PMID: 23017332; PMCID: PMC4151170.
      Citations: 8     Fields:    Translation:Humans
    372. Cortes J, Santos FP. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Pharmacother. 2012 Nov; 13(16):2381-95. PMID: 22992064.
      Citations: 3     Fields:    Translation:HumansAnimals
    373. Cortes JE, Kim DW, Kantarjian HM, Dyagil I, Griskevicius L, Malhotra H, Powell C, Countouriotis AM, Gambacorti-Passerini C, Br?mmendorf TH, Gogat K. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 01; 30(28):3486-92. PMID: 22949154; PMCID: PMC4979199.
      Citations: 154     Fields:    Translation:HumansCTClinical Trials
    374. Hoehn D, Medeiros LJ, Kantarjian HM, Cortes JE, Wang X, Bueso-Ramos CE. Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Hum Pathol. 2012 Dec; 43(12):2354-9. PMID: 22939577.
      Citations: 4     Fields:    Translation:Humans
    375. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27; 120(13):2573-80. PMID: 22896000; PMCID: PMC4916583.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    376. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21. PMID: 22875630; PMCID: PMC3561428.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    377. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12. PMID: 22763385.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    378. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. PMID: 22718840; PMCID: PMC4081158.
      Citations: 82     Fields:    Translation:Humans
    379. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8. PMID: 22707337; PMCID: PMC4180246.
      Citations: 25     Fields:    Translation:Humans
    380. Warren M, Luthra R, Yin CC, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Zuo Z. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12. PMID: 22684224.
      Citations: 17     Fields:    Translation:Humans
    381. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31. PMID: 22665218; PMCID: PMC3981542.
      Citations: 20     Fields:    Translation:Humans
    382. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200. PMID: 22578814; PMCID: PMC4050633.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    383. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176; PMCID: PMC3390955.
      Citations: 49     Fields:    Translation:HumansCells
    384. Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45. PMID: 22642896; PMCID: PMC5707199.
      Citations: 12     Fields:    Translation:Humans
    385. Kantarjian H, Cortes J, Quint?s-Cardama A. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):337-40. PMID: 22633167.
      Citations: 45     Fields:    Translation:Humans
    386. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012 Aug 16; 120(7):1390-7. PMID: 22613793; PMCID: PMC4916560.
      Citations: 46     Fields:    Translation:Humans
    387. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22. PMID: 22605576; PMCID: PMC4184417.
      Citations: 7     Fields:    Translation:HumansCells
    388. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10. PMID: 22585696; PMCID: PMC4879705.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    389. Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4. PMID: 22579233; PMCID: PMC4103411.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    390. Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9. PMID: 22569880; PMCID: PMC3416961.
      Citations: 19     Fields:    Translation:HumansCells
    391. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38. PMID: 22519766.
      Citations: 21     Fields:    Translation:Humans
    392. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8. PMID: 22627678; PMCID: PMC4118284.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    393. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616; PMCID: PMC3859239.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    394. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5. PMID: 22532519; PMCID: PMC3409823.
      Citations: 19     Fields:    Translation:HumansCells
    395. Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM, Quint?s-Cardama A. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer. 2012 Nov 01; 118(21):5283-92. PMID: 22517119; PMCID: PMC3435477.
      Citations: 13     Fields:    Translation:HumansCells
    396. Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S, Quint?s-Cardama A. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7. PMID: 22475363; PMCID: PMC4152772.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    397. Daver N, Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62. PMID: 22507781.
      Citations: 16     Fields:    Translation:HumansAnimals
    398. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1446-54. PMID: 22449610; PMCID: PMC3499973.
      Citations: 7     Fields:    Translation:HumansCells
    399. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10; 119(19):4524-6. PMID: 22431574; PMCID: PMC3362365.
      Citations: 27     Fields:    Translation:Humans
    400. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012 Apr; 13(6):815-28. PMID: 22429140.
      Citations: 4     Fields:    Translation:Humans
    401. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826; PMCID: PMC4081383.
      Citations: 85     Fields:    Translation:HumansCellsCTClinical Trials
    402. Candelaria M, Labardini J, Gonzalez-Fierro A, Taja-Chayeb L, Cortes J, Gordillo-Bastidas D, Cervera E, L?pez-Navarro O, Due?as-Gonz?lez A. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):207-12. PMID: 22420986.
      Citations: 12     Fields:    Translation:Humans
    403. Kantarjian H, Cortes J, Quint?s-Cardama A. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. Drugs Today (Barc). 2012 Mar; 48(3):177-88. PMID: 22462037.
      Citations: 2     Fields:    Translation:HumansAnimals
    404. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22. PMID: 22370904; PMCID: PMC3370116.
      Citations: 11     Fields:    Translation:Humans
    405. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Br?mmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12; 119(15):3403-12. PMID: 22371878; PMCID: PMC4916559.
      Citations: 106     Fields:    Translation:HumansCTClinical Trials
    406. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11. PMID: 22357140.
      Citations: 136     Fields:    Translation:HumansCTClinical Trials
    407. Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y, Guilhot F. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012 May; 97(5):731-8. PMID: 22315495; PMCID: PMC3342976.
      Citations: 36     Fields:    Translation:Humans
    408. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012 Jun 15; 118(12):3123-7. PMID: 22294282; PMCID: PMC3342429.
      Citations: 95     Fields:    Translation:Humans
    409. Fava C, Kantarjian H, Cortes J. Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk. 2012 Apr; 12(2):79-87. PMID: 22285607; PMCID: PMC5539978.
      Citations: 1     Fields:    Translation:Humans
    410. Cortes J. Chronic myeloid leukemia: the race is yet to be won. CMAJ. 2012 May 15; 184(8):857-8. PMID: 22271914; PMCID: PMC3348186.
      Citations:    Fields:    Translation:Humans
    411. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35. PMID: 22271898; PMCID: PMC3396674.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    412. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8. PMID: 22228403; PMCID: PMC4221258.
      Citations: 3     Fields:    Translation:HumansCells
    413. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7. PMID: 22228624; PMCID: PMC3311242.
      Citations: 108     Fields:    Translation:Humans
    414. Cortes JE. Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Clin Oncol. 2012 Jan 20; 30(3):223-4. PMID: 22184376.
      Citations: 2     Fields:    Translation:Humans
    415. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Wang J, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A, Undurraga MS, Ipi?a JJ. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 02; 119(5):1123-9. PMID: 22160483; PMCID: PMC4916556.
      Citations: 195     Fields:    Translation:HumansCTClinical Trials
    416. Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM, le Coutre PD. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012 Jun; 26(6):1189-94. PMID: 22076466.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    417. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica. 2012 Feb; 97(2):235-40. PMID: 22058194; PMCID: PMC3269483.
      Citations: 4     Fields:    Translation:Humans
    418. Kantarjian H, Cortes J, Santos FP, Quint?s-Cardama A. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011 Nov-Dec; 17(6):465-76. PMID: 22157290; PMCID: PMC3243359.
      Citations: 20     Fields:    Translation:HumansAnimals
    419. Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012 Apr; 26(4):788-94. PMID: 22033489; PMCID: PMC3598156.
      Citations: 19     Fields:    Translation:HumansCells
    420. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73. PMID: 22020636; PMCID: PMC4060157.
      Citations: 22     Fields:    Translation:Humans
    421. Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v. PMID: 22054730; PMCID: PMC4428141.
      Citations: 16     Fields:    Translation:Humans
    422. Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2012 May; 26(5):883-92. PMID: 22005789.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    423. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Garcia-Manero G, Rios MB, Cortes JE, Quint?s-Cardama A. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10; 29(32):4260-5. PMID: 21990394; PMCID: PMC3221527.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    424. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012 Jun; 47(6):810-6. PMID: 21986636; PMCID: PMC3896981.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    425. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011 Nov 20; 29(33):4417-23. PMID: 21969499; PMCID: PMC3221524.
      Citations: 116     Fields:    Translation:Humans
    426. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95. PMID: 21969505; PMCID: PMC4876352.
      Citations: 43     Fields:    Translation:Humans
    427. Basak GW, Soverini S, Martinelli G, Mauro MJ, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J, Nicolini FE, M?ller MC, Labussi?re H, Morisset S. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 Nov 17; 118(20):5697-700. PMID: 21926354; PMCID: PMC4916555.
      Citations: 17     Fields:    Translation:Humans
    428. Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2011 Sep; 6(3):187-94. PMID: 21660654; PMCID: PMC4201047.
      Citations: 6     Fields:    Translation:HumansCells
    429. Cortes JE, Kantarjian HM, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C, Br?mmendorf TH. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27; 118(17):4567-76. PMID: 21865346; PMCID: PMC4916618.
      Citations: 141     Fields:    Translation:HumansCTClinical Trials
    430. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8. PMID: 21846902; PMCID: PMC3291487.
      Citations: 34     Fields:    Translation:Humans
    431. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6. PMID: 21831744; PMCID: PMC3215673.
      Citations: 8     Fields:    Translation:Humans
    432. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):355-60. PMID: 21816374; PMCID: PMC4405186.
      Citations: 10     Fields:    Translation:HumansCells
    433. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):361-6. PMID: 21816375; PMCID: PMC4101692.
      Citations: 16     Fields:    Translation:Humans
    434. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759. PMID: 21803854; PMCID: PMC3291489.
      Citations: 47     Fields:    Translation:Humans
    435. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7. PMID: 21767516; PMCID: PMC4061979.
      Citations: 36     Fields:    Translation:Humans
    436. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8. PMID: 21751197; PMCID: PMC4180241.
      Citations: 12     Fields:    Translation:Humans
    437. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 01; 118(3):848-55. PMID: 21751205; PMCID: PMC3919032.
      Citations: 7     Fields:    Translation:Humans
    438. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8. PMID: 21747082; PMCID: PMC4874216.
      Citations: 26     Fields:    Translation:Humans
    439. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011; 6(7):e22110. PMID: 21760961; PMCID: PMC3132778.
      Citations: 52     Fields:    Translation:HumansCells
    440. Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quint?s-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9. PMID: 21732333; PMCID: PMC6896214.
      Citations: 24     Fields:    Translation:Humans
    441. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15; 118(2):418-27. PMID: 21717444; PMCID: PMC4977021.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    442. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011 Aug 11; 118(6):1622-31. PMID: 21653938; PMCID: PMC3156048.
      Citations: 24     Fields:    Translation:HumansCells
    443. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2011 Jun; 4(3):253-60. PMID: 21668392.
      Citations:    Fields:    Translation:Humans
    444. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702. PMID: 21628411; PMCID: PMC3142906.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    445. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902. PMID: 21622644; PMCID: PMC4186644.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    446. Freireich EJ, Kantarjian H, Verstovsek S, Cort?s JE. Retrospect of hematologic malignancies 2010. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S1. PMID: 22035736.
      Citations:    Fields:    Translation:Humans
    447. Kantarjian HM, Quint?s-Cardama A, Cortes JE. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer. 2011 Dec 01; 117(23):5261-70. PMID: 21598241; PMCID: PMC4181589.
      Citations: 8     Fields:    Translation:Humans
    448. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694; PMCID: PMC4874214.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    449. Cornelison AM, Kantarjian H, Cortes J, Jabbour E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10. PMID: 22035738; PMCID: PMC4428283.
      Citations: 5     Fields:    Translation:Humans
    450. Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J, Quint?s-Cardama A. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93. PMID: 21523765; PMCID: PMC4324753.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    451. Lima LM, Sampat K, Assouline S, Saxe D, Nault S, Tighiouart M, McLemore M, Arellano M, Winton E, Bernal-Mizrachi L, Cortes J, Khoury HJ. Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Leuk Lymphoma. 2011 Jun; 52(6):1010-6. PMID: 21504383.
      Citations: 1     Fields:    Translation:Humans
    452. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9. PMID: 21509801; PMCID: PMC4712950.
      Citations: 7     Fields:    Translation:Humans
    453. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41. PMID: 21575929; PMCID: PMC4120264.
      Citations: 5     Fields:    Translation:Humans
    454. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877. PMID: 21480207; PMCID: PMC4160798.
      Citations: 22     Fields:    Translation:Humans
    455. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6. PMID: 21467546; PMCID: PMC4186645.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    456. Vigil CE, Wang SA, Cortes JE, Bueso-Ramos C, Verstovsek S, Shinder R, Chen SS, Katz RL, Khanna A, Esmaeli B, Manning JT, You MJ, Miranda RN. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011 Jun 10; 29(17):e514-6. PMID: 21464405; PMCID: PMC4874210.
      Citations: 4     Fields:    Translation:Humans
    457. Prescott H, Kantarjian H, Cortes J, Ravandi F. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs. 2011 Sep; 16(3):407-23. PMID: 21417961; PMCID: PMC4122233.
      Citations: 3     Fields:    Translation:HumansAnimals
    458. Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol. 2011 Apr 20; 29(12):1512-6. PMID: 21422414; PMCID: PMC4979098.
      Citations: 8     Fields:    Translation:Humans
    459. Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9. PMID: 21357713; PMCID: PMC3046262.
      Citations: 6     Fields:    Translation:HumansCells
    460. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66. PMID: 21191675; PMCID: PMC4394740.
      Citations: 10     Fields:    Translation:Humans
    461. Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J, Quint?s-Cardama A. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21. PMID: 21357704; PMCID: PMC3105655.
      Citations: 6     Fields:    Translation:Humans
    462. Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304. PMID: 21319142; PMCID: PMC4316826.
      Citations: 20     Fields:    Translation:HumansAnimals
    463. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1674-83. PMID: 21307148.
      Citations: 19     Fields:    Translation:Humans
    464. Kantarjian H, Cortes J, Verstovsek S, Quint?s-Cardama A. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011 Feb; 10(2):127-40. PMID: 21283107.
      Citations: 114     Fields:    Translation:HumansAnimals
    465. Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:81-91. PMID: 21299461; PMCID: PMC5681224.
      Citations: 7     Fields:    Translation:Humans
    466. Ferrajoli A, Keating MJ, O'Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2011 Jul 15; 117(14):3182-6. PMID: 21246526; PMCID: PMC4401466.
      Citations: 3     Fields:    Translation:Humans
    467. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol. 2011 Feb 10; 29(5):524-31. PMID: 21220597; PMCID: PMC4979134.
      Citations: 33     Fields:    Translation:HumansCells
    468. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96. PMID: 21220608; PMCID: PMC4979099.
      Citations: 166     Fields:    Translation:HumansCTClinical Trials
    469. Scholl V, Hassan R, Capelleti P, de Lima M, Cortes J, Renault IZ. The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era. Rev Bras Hematol Hemoter. 2011; 33(6):455-60. PMID: 23049363; PMCID: PMC3459378.
      Citations:    
    470. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66. PMID: 21218459; PMCID: PMC4185295.
      Citations: 12     Fields:    Translation:Humans
    471. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7. PMID: 21156844; PMCID: PMC4186643.
      Citations: 23     Fields:    Translation:HumansCells
    472. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011 Jan; 121(1):396-409. PMID: 21157039; PMCID: PMC3007128.
      Citations: 359     Fields:    Translation:HumansCells
    473. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5. PMID: 21127188; PMCID: PMC4916558.
      Citations: 1     Fields:    Translation:HumansCells
    474. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs. 2010 Dec; 11(12):1450-65. PMID: 21154127.
      Citations: 17     Fields:    Translation:Humans
    475. Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Panel at the Third Global Workshop on Chronic Myeloid Leukemia, Cort?s JE. Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):443-51. PMID: 21156461.
      Citations: 1     Fields:    Translation:Humans
    476. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11. PMID: 21509757; PMCID: PMC4180713.
      Citations: 29     Fields:    Translation:Humans
    477. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011 May 15; 117(10):2145-55. PMID: 21523727; PMCID: PMC4184429.
      Citations: 38     Fields:    Translation:Humans
    478. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5. PMID: 21098399; PMCID: PMC4916554.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    479. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8. PMID: 20665501; PMCID: PMC5434864.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    480. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72. PMID: 21073351.
      Citations: 2     Fields:    Translation:HumansAnimals
    481. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20; 117(3):920-7. PMID: 21063027; PMCID: PMC3298438.
      Citations: 33     Fields:    Translation:HumansCells
    482. Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, Hamerschlak N, Pagnano K, Pasquini R, Meillon L. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer. 2010 Nov 01; 116(21):4991-5000. PMID: 20665487; PMCID: PMC4972041.
      Citations: 7     Fields:    Translation:Humans
    483. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7. PMID: 21030554; PMCID: PMC4081281.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    484. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011 Mar 01; 117(5):982-91. PMID: 20960502; PMCID: PMC4324729.
      Citations: 5     Fields:    Translation:Humans
    485. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44. PMID: 20960519; PMCID: PMC4061136.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    486. Cortes J, Kantarjian HM, Quint?s-Cardama A. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15; 117(6):1113-22. PMID: 20960522; PMCID: PMC4969001.
      Citations: 4     Fields:    Translation:Humans
    487. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8. PMID: 20952518; PMCID: PMC3012766.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    488. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 2011 Mar 01; 117(5):897-906. PMID: 20945321; PMCID: PMC4428165.
      Citations: 12     Fields:    Translation:HumansAnimals
    489. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153. PMID: 20923968; PMCID: PMC4081278.
      Citations: 36     Fields:    Translation:Humans
    490. Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2011 Feb 15; 117(4):688-97. PMID: 20922786.
      Citations: 21     Fields:    Translation:Humans
    491. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15; 117(4):662-76. PMID: 20922795.
      Citations: 5     Fields:    Translation:Humans
    492. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010 Oct; 47(4):344-53. PMID: 20875551.
      Citations: 5     Fields:    Translation:Humans
    493. Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol. 2010 Oct; 47(4):362-70. PMID: 20875553; PMCID: PMC2948413.
      Citations: 10     Fields:    Translation:HumansCells
    494. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010 Oct 01; 116(19):4580-9. PMID: 20572037; PMCID: PMC4458382.
      Citations: 5     Fields:    Translation:Humans
    495. Cortes J. Towards a cure for chronic myeloid leukemia: are we there yet? Semin Hematol. 2010 Oct; 47(4):299-301. PMID: 20875545.
      Citations:    Fields:    Translation:Humans
    496. Kantarjian H, Cortes J, Quint?s-Cardama A. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol. 2010 Oct; 47(4):371-80. PMID: 20875554.
      Citations: 5     Fields:    Translation:Humans
    497. Cortes J, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H, Quint?s-Cardama A. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80. PMID: 20886606; PMCID: PMC4312759.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    498. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27. PMID: 20843246; PMCID: PMC5187954.
      Citations: 489     Fields:    Translation:HumansCTClinical Trials
    499. Al-Kali A, Kantarjian H, Shan J, Bassett R, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J, Quint?s-Cardama A. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011 Jan 15; 117(2):327-35. PMID: 20845478; PMCID: PMC4327987.
      Citations: 10     Fields:    Translation:Humans
    500. Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R, Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10. PMID: 20557306; PMCID: PMC3364021.
      Citations: 6     Fields:    Translation:HumansCells
    501. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Sep 01; 116(17):4063-8. PMID: 20564156; PMCID: PMC4181579.
      Citations: 31     Fields:    Translation:Humans
    502. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep. 2010 Sep; 12(5):302-13. PMID: 20640942.
      Citations: 9     Fields:    Translation:Humans
    503. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5. PMID: 20803607; PMCID: PMC4287232.
      Citations: 13     Fields:    Translation:Humans
    504. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74. PMID: 20737576; PMCID: PMC4332768.
      Citations: 45     Fields:    Translation:Humans
    505. Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol. 2010 Sep 20; 28(27):4207-13. PMID: 20713865; PMCID: PMC4979236.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    506. Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010 Aug 15; 116(16):3852-61. PMID: 20564086; PMCID: PMC4993589.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    507. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4. PMID: 20564137; PMCID: PMC4295788.
      Citations: 83     Fields:    Translation:Humans
    508. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010 Aug 01; 116(15):3631-7. PMID: 20564073.
      Citations: 13     Fields:    Translation:Humans
    509. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84. PMID: 20658954; PMCID: PMC4188823.
      Citations: 3     Fields:    Translation:HumansCells
    510. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9. PMID: 20668231; PMCID: PMC4081299.
      Citations: 148     Fields:    Translation:Humans
    511. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9. PMID: 20660823; PMCID: PMC2940403.
      Citations: 127     Fields:    Translation:HumansCellsCTClinical Trials
    512. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer. 2010 Jul 01; 116(13):3152-9. PMID: 20564631; PMCID: PMC4314210.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    513. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9. PMID: 20595523.
      Citations: 4     Fields:    Translation:Humans
    514. Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 2010 Jun 15; 4:207-13. PMID: 20694077; PMCID: PMC2899790.
      Citations: 10     
    515. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010 Aug; 150(3):303-12. PMID: 20553275; PMCID: PMC4105000.
      Citations: 16     Fields:    Translation:Humans
    516. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M, Huguet F, Boqu? C. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2260-70. PMID: 20525995.
      Citations: 506     Fields:    Translation:HumansCTClinical Trials
    517. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM, D?nzinger U. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301. PMID: 20520639; PMCID: PMC3078756.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    518. Jabbour E, Fullmer A, Kantarjian H, Cort?s JE. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10 Suppl 1:S6-13. PMID: 20529808.
      Citations: 2     Fields:    Translation:Humans
    519. Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer. 2010 Jun 01; 116(11):2665-72. PMID: 20310049; PMCID: PMC2876208.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    520. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81. PMID: 20499401; PMCID: PMC4216809.
      Citations: 23     Fields:    Translation:Humans
    521. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Ravandi F, Cort?s JE. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10. PMID: 20511166; PMCID: PMC3726276.
      Citations: 6     Fields:    Translation:Humans
    522. Kantarjian H, Quint?s-Cardama A, Cort?s JE. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10 Suppl 1:S14-9. PMID: 20529803.
      Citations:    Fields:    Translation:Humans
    523. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. Cancer. 2010 May 15; 116(10):2366-71. PMID: 20209609; PMCID: PMC3833724.
      Citations: 8     Fields:    Translation:Humans
    524. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010 May 15; 116(10):2290-300. PMID: 20209620.
      Citations: 27     Fields:    Translation:Humans
    525. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7. PMID: 20466853; PMCID: PMC4081177.
      Citations: 121     Fields:    Translation:HumansCTClinical Trials
    526. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9. PMID: 20162709; PMCID: PMC3753205.
      Citations: 43     Fields:    Translation:Humans
    527. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010 May; 51(5):778-82. PMID: 20196624; PMCID: PMC4086357.
      Citations: 24     Fields:    Translation:Humans
    528. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60. PMID: 20421540; PMCID: PMC4872315.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    529. Muneer S, Ranganathan A, Schlager S, American Society of Hematology. The 51st annual meeting of the American Society of Hematology. Clin Lymphoma Myeloma Leuk. 2010 Apr; 10(2):90-7. PMID: 20371441.
      Citations:    Fields:    Translation:Humans
    530. Agrawal M, Garg RJ, Cortes J, Quint?s-Cardama A. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep. 2010 Apr; 5(2):70-80. PMID: 20425399.
      Citations: 19     Fields:    Translation:Humans
    531. Kantarjian HM, Cortes J, Hochhaus A, La Ros?e P. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2010 Mar 15; 116(6):1419-30. PMID: 20120030.
      Citations: 19     Fields:    Translation:Humans
    532. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. PMID: 20212254; PMCID: PMC2930809.
      Citations: 154     Fields:    Translation:HumansCTClinical Trials
    533. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010 Mar 05; 140(5):652-65. PMID: 20211135; PMCID: PMC2924756.
      Citations: 247     Fields:    Translation:HumansAnimalsCells
    534. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010 Feb; 51(2):269-74. PMID: 20038218; PMCID: PMC4184061.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    535. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma. 2010 Mar; 51(3):475-80. PMID: 20078325; PMCID: PMC4086446.
      Citations: 5     Fields:    Translation:Humans
    536. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010 Jan 15; 116(2):377-86. PMID: 19924787; PMCID: PMC4185296.
      Citations: 42     Fields:    Translation:Humans
    537. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi F. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer. 2010 Jan 15; 116(2):369-76. PMID: 19950129; PMCID: PMC4180261.
      Citations: 10     Fields:    Translation:Humans
    538. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010 Jan; 26(1):61-9. PMID: 19905880.
      Citations: 32     Fields:    Translation:Humans
    539. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51. PMID: 19795507; PMCID: PMC2794953.
      Citations: 35     Fields:    Translation:HumansCells
    540. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20; 28(3):398-404. PMID: 20008620; PMCID: PMC2815702.
      Citations: 88     Fields:    Translation:Humans
    541. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20; 28(3):392-7. PMID: 20008621; PMCID: PMC2815701.
      Citations: 93     Fields:    Translation:Humans
    542. Cortes JE, Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP, Guilhot F. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010 Jan 20; 28(3):424-30. PMID: 20008622; PMCID: PMC4979244.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    543. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6. PMID: 20008298; PMCID: PMC4081385.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    544. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011 Jan; 19(1):19-26. PMID: 19956980.
      Citations: 16     Fields:    Translation:Humans
    545. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr; 16(4):543-7. PMID: 19961946; PMCID: PMC2839005.
      Citations: 8     Fields:    Translation:Humans
    546. Kantarjian H, Cortes J, Quint?s-Cardama A. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 01; 115(23):5382-93. PMID: 19739234.
      Citations: 36     Fields:    Translation:Humans
    547. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010 Jan 10; 28(2):285-91. PMID: 19933907; PMCID: PMC3340938.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    548. Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet, Baccarani M, Guilhot F. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10; 27(35):6041-51. PMID: 19884523; PMCID: PMC4979100.
      Citations: 393     Fields:    Translation:Humans
    549. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun; 34(6):752-6. PMID: 19878996; PMCID: PMC4082769.
      Citations: 49     Fields:    Translation:Humans
    550. Mauro MJ, Martinelli G, Kim DW, Soverini S, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, Yagasaki F, Pearson JD, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman JM, Zhou W, Nicolini FE, M?ller MC. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009 Dec 17; 114(26):5271-8. PMID: 19843886; PMCID: PMC4916939.
      Citations: 36     Fields:    Translation:Humans
    551. Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S, Quint?s-Cardama A. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24. PMID: 19826111; PMCID: PMC4881362.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    552. Cort?s JE. Clinical Lymphoma & Myeloma . . . and leukemia too! Clin Lymphoma Myeloma. 2009 Oct; 9(5):344. PMID: 19858052.
      Citations:    Fields:    Translation:Humans
    553. Jabbour E, Hochhaus A, Cortes J, Kantarjian HM, La Ros?e P. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12. PMID: 19798095.
      Citations: 28     Fields:    Translation:Humans
    554. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009 Nov 20; 27(33):5587-93. PMID: 19786661; PMCID: PMC4979081.
      Citations: 36     Fields:    Translation:Humans
    555. Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A, M?ller MC. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009 Dec 03; 114(24):4944-53. PMID: 19779040; PMCID: PMC4916940.
      Citations: 98     Fields:    Translation:Humans
    556. Kantarjian H, Pasquini R, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP, L?vy V. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47. PMID: 19536906; PMCID: PMC5345391.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    557. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80. PMID: 19741728; PMCID: PMC4217206.
      Citations: 27     Fields:    Translation:Humans
    558. Garg RJ, Kantarjian H, O'Brien S, Faderl S, Estrov Z, Cortes J, Quint?s-Cardama A. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8. PMID: 19729517; PMCID: PMC3952810.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    559. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009 Sep 01; 115(17):3924-34. PMID: 19536894; PMCID: PMC5534348.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    560. Cortes J, Quint?s-Cardama A. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Curr Oncol Rep. 2009 Sep; 11(5):337-45. PMID: 19679008.
      Citations: 7     Fields:    Translation:Humans
    561. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16. PMID: 19723894; PMCID: PMC2754862.
      Citations: 17     Fields:    Translation:HumansCells
    562. De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J, Quint?s-Cardama A. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer. 2009 Sep 01; 115(17):3935-43. PMID: 19517473; PMCID: PMC4386888.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    563. Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S, Quint?s-Cardama A. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6. PMID: 19720904; PMCID: PMC4879697.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    564. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009 Oct 01; 27(28):4754-9. PMID: 19720924; PMCID: PMC4979200.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    565. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525. PMID: 19728024; PMCID: PMC4209590.
      Citations: 4     Fields:    Translation:Humans
    566. Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M, Chronic Leukemia Working Committee. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1475-8. PMID: 19822308; PMCID: PMC2929002.
      Citations: 19     Fields:    Translation:Humans
    567. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18. PMID: 19517462; PMCID: PMC4388415.
      Citations: 37     Fields:    Translation:Humans
    568. Kantarjian H, Cortes J, Quint?s-Cardama A. Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009 Sep; 6(9):535-43. PMID: 19652654.
      Citations: 50     Fields:    Translation:Humans
    569. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A, M?ller MC. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009 Sep 01; 27(25):4204-10. PMID: 19652056; PMCID: PMC4979230.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    570. Cheson BD, Jagannath S, Cort?s JE. Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia. Clin Lymphoma Myeloma. 2009 Aug; 9(4):266. PMID: 19717375.
      Citations:    Fields:    Translation:Humans
    571. Cole S, Kantarjian H, Ault P, Cort?s JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009 Aug; 9(4):324-7. PMID: 19717385.
      Citations: 14     Fields:    Translation:Humans
    572. Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health. 2010 Jan-Feb; 13(1):103-11. PMID: 19659707.
      Citations: 17     Fields:    Translation:Humans
    573. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009 Jul 15; 115(14):3217-21. PMID: 19441109; PMCID: PMC4184418.
      Citations: 22     Fields:    Translation:Humans
    574. Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes JE, Medeiros LJ, Lu G. del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009 Jul; 192(1):18-23. PMID: 19480932; PMCID: PMC4167428.
      Citations: 2     Fields:    Translation:HumansCells
    575. Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM, Quint?s-Cardama A. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer. 2009 Jul 01; 115(13):2912-21. PMID: 19402171; PMCID: PMC4176768.
      Citations: 16     Fields:    Translation:Humans
    576. Cataldo VD, Cortes J, Quint?s-Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther. 2009 Jul; 9(7):875-84. PMID: 19589026.
      Citations: 14     Fields:    Translation:Humans
    577. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43. PMID: 19567878; PMCID: PMC4186638.
      Citations: 37     Fields:    Translation:HumansCells
    578. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep 10; 114(11):2232-5. PMID: 19531657; PMCID: PMC4828071.
      Citations: 51     Fields:    Translation:Humans
    579. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9. PMID: 19506164; PMCID: PMC2799062.
      Citations: 26     Fields:    Translation:Humans
    580. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med. 2010 Jun; 14(6B):1777-92. PMID: 19508387; PMCID: PMC3444523.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    581. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009 Jul 20; 27(21):3472-9. PMID: 19487385; PMCID: PMC4979080.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    582. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009 Aug 01; 27(22):3659-63. PMID: 19487383; PMCID: PMC2799063.
      Citations: 23     Fields:    Translation:HumansCells
    583. Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J, Quint?s-Cardama A. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009 Jun 01; 115(11):2482-90. PMID: 19280591; PMCID: PMC4180711.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    584. Nussenzveig RH, Cortes J, Sever M, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009 Jul; 90(1):58-63. PMID: 19484334; PMCID: PMC4378576.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    585. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 01; 15(11):3820-6. PMID: 19458051; PMCID: PMC4091712.
      Citations: 20     Fields:    Translation:Humans
    586. Han X, Kantarjian H, Cortes J, Quint?s-Cardama A. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009 Jul 09; 114(2):261-3. PMID: 19414863; PMCID: PMC3952950.
      Citations: 66     Fields:    Translation:Humans
    587. Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009 May; 94(5):743-4. PMID: 19407320; PMCID: PMC2675690.
      Citations: 11     Fields:    Translation:Humans
    588. Kantarjian H, Cortes JE, Pavlovsky C. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol. 2009 May; 84(5):287-93. PMID: 19306355.
      Citations: 15     Fields:    Translation:Humans
    589. Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2009 May; 18(5):1501-6. PMID: 19423527; PMCID: PMC2918285.
      Citations: 16     Fields:    Translation:HumansPHPublic Health
    590. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009 Sep; 23(9):1537-44. PMID: 19404318.
      Citations: 20     Fields:    Translation:HumansCells
    591. Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J, Quint?s-Cardama A. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009 Jun 18; 113(25):6315-21. PMID: 19369233; PMCID: PMC3953080.
      Citations: 66     Fields:    Translation:HumansCells
    592. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS, M?ller MC. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18; 113(25):6322-9. PMID: 19369231; PMCID: PMC4916944.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    593. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-496. PMID: 19340529; PMCID: PMC4199302.
      Citations: 24     Fields:    Translation:Humans
    594. Kantarjian HM, Cortes JE, Quint?s-Cardama A. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009 Apr; 16(2):122-31. PMID: 19337198.
      Citations: 80     Fields:    Translation:Humans
    595. Verma D, Fava C, Kantarjian H, Cortes J. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol. 2009 Apr; 84(4):256-7. PMID: 19260121.
      Citations: 1     Fields:    Translation:HumansCells
    596. Khoury HJ, Hughes TP, Kim DW, Cortes JE, Guilhot F. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009 Apr 01; 115(7):1381-94. PMID: 19195046.
      Citations: 16     Fields:    Translation:Humans
    597. Fava C, Cortes J. Optimizing first-line therapy for patients with chronic myeloid leukemia. Semin Hematol. 2009 Apr; 46(2 Suppl 3):S5-10. PMID: 19621543.
      Citations: 1     Fields:    Translation:Humans
    598. Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009; 121(1):27-31. PMID: 19332983; PMCID: PMC2790522.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    599. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63. PMID: 19282457; PMCID: PMC4081366.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    600. Cortes J, De Keersmaecker K. T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1. Leuk Lymphoma. 2009 Mar; 50(3):321-2. PMID: 19294558.
      Citations: 1     Fields:    Translation:HumansCells
    601. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009 Jul; 23(7):1297-302. PMID: 19242494; PMCID: PMC4217203.
      Citations: 19     Fields:    Translation:HumansAnimalsCTClinical Trials
    602. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43. PMID: 19224852; PMCID: PMC4890649.
      Citations: 28     Fields:    Translation:Humans
    603. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Luthra R, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov; 33(11):1481-4. PMID: 19193436; PMCID: PMC4184059.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    604. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ, International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60. PMID: 19117345; PMCID: PMC4445370.
      Citations: 31     Fields:    
    605. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9. PMID: 19181650; PMCID: PMC2664587.
      Citations: 12     Fields:    Translation:Humans
    606. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009 Jan; 4(1):3-10. PMID: 19343297.
      Citations: 16     Fields:    Translation:Humans
    607. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009 Apr 30; 113(18):4171-8. PMID: 19131547; PMCID: PMC4828077.
      Citations: 27     Fields:    Translation:HumansCells
    608. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 2009 Jan 01; 115(1):101-6. PMID: 19090005; PMCID: PMC4180242.
      Citations: 7     Fields:    Translation:Humans
    609. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S, Cort?s JE. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5. PMID: 19778850.
      Citations: 5     Fields:    Translation:Humans
    610. Cort?s JE. Chronic myeloid leukemia: where do we go now? Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S374-5. PMID: 20007105.
      Citations:    Fields:    Translation:Humans
    611. Fava C, Kantarjian H, Jabbour E, Cort?s JE. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90. PMID: 20007107.
      Citations: 1     Fields:    Translation:Humans
    612. Quint?s-Cardama A, Cort?s JE. The next generation of therapies for chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S395-403. PMID: 20007109.
      Citations:    Fields:    Translation:Humans
    613. Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE, Quint?s-Cardama A. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73. PMID: 19118067; PMCID: PMC4822510.
      Citations: 19     Fields:    Translation:HumansCells
    614. Jabbour E, Kantarjian H, Cort?s JE. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9. PMID: 19778852.
      Citations: 5     Fields:    Translation:Humans
    615. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10. PMID: 19075265; PMCID: PMC4881307.
      Citations: 119     Fields:    Translation:Humans
    616. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60. PMID: 19060245; PMCID: PMC4081392.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    617. Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, Albitar M. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008 Dec; 7(12):3834-41. PMID: 19056677.
      Citations: 21     Fields:    Translation:HumansCells
    618. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008 Dec; 49(12):2246-55. PMID: 19052971; PMCID: PMC4086439.
      Citations: 27     Fields:    Translation:HumansCells
    619. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008 Dec 01; 113(11):3186-91. PMID: 18846563; PMCID: PMC4188532.
      Citations: 55     Fields:    Translation:Humans
    620. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, Shiotsu Y, Shudo A, Akinaga S, Small D, Karp JE, Levis M. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009 Apr 23; 113(17):3938-46. PMID: 19029442; PMCID: PMC2673122.
      Citations: 87     Fields:    Translation:HumansCellsCTClinical Trials
    621. Jain N, Cortes J, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9. PMID: 19013640; PMCID: PMC4422052.
      Citations: 11     Fields:    Translation:Humans
    622. Cortes J, Quint?s-Cardama A. Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT. Bone Marrow Transplant. 2009 Apr; 43(7):579-81. PMID: 18978822.
      Citations: 1     Fields:    Translation:Humans
    623. Cortes J, Quint?s-Cardama A. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 2008 Oct; 4(5):611-21. PMID: 18922118.
      Citations: 8     Fields:    Translation:HumansAnimals
    624. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008 Oct 01; 113(7 Suppl):1933-52. PMID: 18798533; PMCID: PMC4392892.
      Citations: 36     Fields:    Translation:Humans
    625. Cortes J, Quint?s-Cardama A. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009 Feb 19; 113(8):1619-30. PMID: 18827185; PMCID: PMC3952549.
      Citations: 223     Fields:    Translation:HumansAnimalsCells
    626. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42. PMID: 18818391; PMCID: PMC4186640.
      Citations: 23     Fields:    Translation:Humans
    627. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2. PMID: 18809762; PMCID: PMC2597614.
      Citations: 14     Fields:    Translation:Humans
    628. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1338-43. PMID: 18629842.
      Citations: 2     Fields:    Translation:Humans
    629. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008 Sep 15; 113(6):1351-61. PMID: 18618511; PMCID: PMC4188533.
      Citations: 160     Fields:    Translation:HumansCells
    630. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94. PMID: 18615627; PMCID: PMC4204653.
      Citations: 48     Fields:    Translation:Humans
    631. Fava C, Cortes J. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. Am J Hematol. 2008 Sep; 83(9):755. PMID: 18615551.
      Citations:    Fields:    Translation:HumansCells
    632. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M, Br?mmendorf TH. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008 Dec; 22(12):2176-83. PMID: 18754032.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    633. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7. PMID: 18715642; PMCID: PMC4163801.
      Citations: 9     Fields:    Translation:Humans
    634. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7. PMID: 18703706; PMCID: PMC2943753.
      Citations: 58     Fields:    Translation:Humans
    635. Cortes J, Quint?s-Cardama A. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008 Jul 15; 14(14):4392-9. PMID: 18628453.
      Citations: 29     Fields:    Translation:Humans
    636. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul 15; 113(2):360-6. PMID: 18473351; PMCID: PMC4126069.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    637. Ault P, Cortes J, Lynn A, Keating M, Verstovsek S. Pregnancy in a patient with hypereosinophilic syndrome. Leuk Res. 2009 Jan; 33(1):186-7. PMID: 18597844; PMCID: PMC4445416.
      Citations: 1     Fields:    Translation:Humans
    638. Cortes J, Quint?s-Cardama A. Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opin Investig Drugs. 2008 Jul; 17(7):1039-50. PMID: 18549340.
      Citations: 1     Fields:    Translation:HumansAnimals
    639. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma. 2008 Jul; 49(7):1399-402. PMID: 18452066.
      Citations: 8     Fields:    Translation:Humans
    640. Jabbour E, El Ahdab S, Cortes J, Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36. PMID: 18549348.
      Citations: 3     Fields:    Translation:HumansAnimals
    641. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37. PMID: 18566326; PMCID: PMC2518875.
      Citations: 56     Fields:    Translation:Humans
    642. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15; 14(12):3906-15. PMID: 18559612; PMCID: PMC5018899.
      Citations: 57     Fields:    Translation:HumansCellsCTClinical Trials
    643. Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Sep; 22(9):1707-11. PMID: 18548095.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    644. Cortes JE. Imatinib therapy for chronic myeloid leukemia: where do we go now? J Clin Oncol. 2008 Jul 10; 26(20):3308-9. PMID: 18519950.
      Citations:    Fields:    Translation:Humans
    645. Manshouri T, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S, Quint?s-Cardama A. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73. PMID: 18482053; PMCID: PMC4829954.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    646. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9. PMID: 18495956; PMCID: PMC4081529.
      Citations: 102     Fields:    Translation:HumansCellsCTClinical Trials
    647. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008 Aug 01; 112(3):516-8. PMID: 18492956; PMCID: PMC4082324.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    648. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008 May 15; 112(10):2112-8. PMID: 18348294; PMCID: PMC5141579.
      Citations: 14     Fields:    Translation:Humans
    649. Cortes J, Quint?s-Cardama A. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs. 2008 May; 11(5):356-72. PMID: 18465678.
      Citations: 7     Fields:    Translation:HumansAnimals
    650. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8. PMID: 18425419; PMCID: PMC4905709.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    651. Lee TS, Potts SJ, Kantarjian H, Cortes J, Giles F, Albitar M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer. 2008 Apr 15; 112(8):1744-53. PMID: 18338744.
      Citations: 15     Fields:    Translation:HumansCells
    652. Cortes J, Quint?s-Cardama A. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park). 2008 Apr 15; 22(4):430-7; discussion 437, 442, 446 passim. PMID: 18472616.
      Citations: 2     Fields:    Translation:Humans
    653. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80. PMID: 18411418; PMCID: PMC3952498.
      Citations: 247     Fields:    Translation:HumansCTClinical Trials
    654. Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G, Quint?s-Cardama A. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008 Jun; 22(6):1117-24. PMID: 18401417.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    655. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5. PMID: 18403620; PMCID: PMC4081375.
      Citations: 41     Fields:    Translation:Humans
    656. Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J, Keating MJ. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis. 2008 Apr 01; 46(7):e69-71. PMID: 18444808.
      Citations: 2     Fields:    Translation:HumansCells
    657. Cortes J, Quint?s-Cardama A. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother. 2008 Apr; 9(6):1029-37. PMID: 18377344.
      Citations: 7     Fields:    Translation:HumansAnimals
    658. Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res. 2008 Sep; 32(9):1468-71. PMID: 18355919; PMCID: PMC4086363.
      Citations:    Fields:    Translation:Humans
    659. Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, Apperley JF. The effects of imatinib on pregnancy outcome. Blood. 2008 Jun 15; 111(12):5505-8. PMID: 18322153; PMCID: PMC4916938.
      Citations: 90     Fields:    Translation:Humans
    660. Cortes J, Kantarjian H. Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S22-S30. PMID: 18397678.
      Citations: 5     Fields:    Translation:Humans
    661. Kantarjian H, Quint?s-Cardama A, Cort?s JE. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S82-8. PMID: 19254885.
      Citations: 8     Fields:    Translation:Humans
    662. Jabbour E, Kantarjian H, Cort?s JE. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S75-81. PMID: 19254884.
      Citations:    Fields:    Translation:HumansCells
    663. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S37-42; quiz S43-S44. PMID: 18397680.
      Citations: 3     Fields:    Translation:Humans
    664. Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J, Quint?s-Cardama A. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain. Leukemia. 2008 Apr; 22(4):885-8. PMID: 18305550.
      Citations: 1     Fields:    Translation:Humans
    665. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45. PMID: 18085610.
      Citations: 41     Fields:    Translation:HumansCells
    666. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J, Guilhot F. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol. 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PMID: 18346528.
      Citations: 13     Fields:    Translation:Humans
    667. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 01; 14(3):721-30. PMID: 18245532.
      Citations: 22     Fields:    Translation:Humans
    668. Verstovsek S, Manshouri T, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z, Quint?s-Cardama A. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96. PMID: 18245540.
      Citations: 31     Fields:    Translation:HumansCells
    669. Cortes J, Quint?s-Cardama A. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res. 2008 Aug; 32(8):1313-6. PMID: 18242697.
      Citations: 2     Fields:    Translation:Humans
    670. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Small D, Cortes J, Andreeff M, Quint?s-Cardama A. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 06; 100(3):184-98. PMID: 18230792.
      Citations: 159     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    671. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr; 22(4):808-18. PMID: 18200035.
      Citations: 79     Fields:    Translation:HumansCells
    672. Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 Jan 15; 14(2):509-14. PMID: 18223226.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    673. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008 Jan; 8(1):99-110. PMID: 18095887.
      Citations: 17     Fields:    Translation:Humans
    674. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res. 2008 Jun; 32(6):936-43. PMID: 18155764.
      Citations: 4     Fields:    Translation:HumansCells
    675. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43. PMID: 18079733.
      Citations: 101     Fields:    Translation:Humans
    676. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008 Feb 15; 111(4):1774-80. PMID: 18055868.
      Citations: 45     Fields:    Translation:Humans
    677. Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9. PMID: 18048643.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    678. Cortes J, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H, Quint?s-Cardama A. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007 Nov 01; 110(9):2000-6. PMID: 17849425.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    679. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J. 2007 Nov-Dec; 13(6):357-65. PMID: 18032972.
      Citations: 2     Fields:    Translation:Humans
    680. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8. PMID: 17849460.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    681. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6. PMID: 17962510.
      Citations: 198     Fields:    Translation:HumansCellsCTClinical Trials
    682. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 01; 111(3):1039-43. PMID: 17932248.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    683. Kantarjian H, Cortes J, Quint?s-Cardama A. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007 Oct 11; 357(15):1557; author reply 1557-8. PMID: 17933034.
      Citations: 4     Fields:    Translation:Humans
    684. Gibbons DL, Cortes J, Bobadilla D, Slovak ML, Kantarjian H, Abruzzo LV, Quint?s-Cardama A. Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia. Leukemia. 2008 Apr; 22(4):877-8. PMID: 17928880.
      Citations: 1     Fields:    Translation:HumansCells
    685. Quintas-Cardama A, Cortes J. Nilotinib therapy in chronic myelogenous leukemia. Drugs Today (Barc). 2007 Oct; 43(10):691-702. PMID: 17987222.
      Citations: 4     Fields:    Translation:HumansAnimals
    686. Kantarjian H, Cortes J, Quint?s-Cardama A. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007 Oct; 6(10):834-48. PMID: 17853901.
      Citations: 91     Fields:    Translation:HumansAnimalsCells
    687. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct 01; 110(7):1509-19. PMID: 17702093.
      Citations: 34     Fields:    Translation:Humans
    688. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9. PMID: 17900686.
      Citations: 7     Fields:    Translation:HumansCells
    689. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302. PMID: 17623836.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    690. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007 Sep 15; 110(6):1303-6. PMID: 17614303.
      Citations: 47     Fields:    Translation:Humans
    691. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11. PMID: 17785585.
      Citations: 89     Fields:    Translation:HumansCells
    692. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007 Sep; 117(9):2408-21. PMID: 17717597; PMCID: PMC1950458.
      Citations: 165     Fields:    Translation:HumansAnimalsCells
    693. Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J, Quint?s-Cardama A. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007 Sep 01; 25(25):3908-14. PMID: 17761974.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    694. Kantarjian H, Abruzzo LV, Cortes J, Quint?s-Cardama A. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia. 2007 Nov; 21(11):2394-6. PMID: 17690707.
      Citations: 3     Fields:    Translation:Humans
    695. Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J, Daley GQ. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82. PMID: 17684485.
      Citations: 6     Fields:    Translation:Humans
    696. Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007 Nov 15; 110(10):3547-51. PMID: 17673605.
      Citations: 33     Fields:    Translation:Humans
    697. Ostronoff F, Bueso-Ramos C, Cortes J, Giralt S. Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution. Am J Hematol. 2007 Aug; 82(8):744-7. PMID: 17506066.
      Citations: 1     Fields:    Translation:Humans
    698. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4. PMID: 17559140.
      Citations: 16     Fields:    Translation:Humans
    699. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5. PMID: 17625066.
      Citations: 35     Fields:    Translation:Humans
    700. Thomas DA, O'Brien S, Cortes J, Kantarjian H. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):183-9. PMID: 20425368.
      Citations: 1     Fields:    Translation:Humans
    701. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007 Jul; 10(7):468-79. PMID: 17642017.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    702. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007 Jul; 31(7):891-7. PMID: 17560285.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    703. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6. PMID: 17593028.
      Citations: 15     Fields:    Translation:Humans
    704. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8. PMID: 17596541.
      Citations: 146     Fields:    Translation:HumansCellsCTClinical Trials
    705. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007 Jun; 48(6):1150-60. PMID: 17577778.
      Citations: 19     Fields:    Translation:Humans
    706. Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Jun; 35(6):931-8. PMID: 17533047.
      Citations: 11     Fields:    Translation:HumansCells
    707. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007 Jun 01; 109(11):2171-81. PMID: 17431887.
      Citations: 30     Fields:    Translation:Humans
    708. Raz T, Nardi V, Azam M, Cortes J, Daley GQ. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9. PMID: 17536018; PMCID: PMC1976354.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    709. Pan J, Manshouri T, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci. 2007 Aug; 98(8):1223-5. PMID: 17517053.
      Citations: 3     Fields:    Translation:HumansCells
    710. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 2007 Jul; 21(7):1347-52. PMID: 17495971.
      Citations: 3     Fields:    Translation:Humans
    711. Pan J, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404. PMID: 17495975.
      Citations: 14     Fields:    Translation:HumansCells
    712. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 2007 May; 16(5):679-87. PMID: 17461740.
      Citations: 11     Fields:    Translation:HumansAnimals
    713. Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8. PMID: 17564324.
      Citations: 1     Fields:    Translation:Humans
    714. Swords R, Alvarado Y, Cortes J, Giles FJ. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep. 2007 May; 2(2):83-8. PMID: 20425355.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    715. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007 Aug 15; 110(4):1233-7. PMID: 17449798.
      Citations: 65     Fields:    Translation:Humans
    716. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60. PMID: 17342766.
      Citations: 29     Fields:    Translation:Humans
    717. Cortes J, Quint?s-Cardama A. Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2007 Apr; 16(4):547-57. PMID: 17371201.
      Citations: 2     Fields:    Translation:HumansAnimals
    718. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9. PMID: 17326049.
      Citations: 25     Fields:    Translation:Humans
    719. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007 Apr 01; 109(7):2999-3006. PMID: 17158228; PMCID: PMC1852228.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    720. Kantarjian H, Cortes J, Quint?s-Cardama A. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. Leuk Lymphoma. 2007 Apr; 48(4):802-4. PMID: 17454640.
      Citations:    Fields:    Translation:HumansCells
    721. Kantarjian HM, Cortes J, Hochhaus A, Baccarani M, Lokey L, Guilhot F. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007 Apr 01; 109(7):1365-75. PMID: 17326047.
      Citations: 10     Fields:    Translation:Humans
    722. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7. PMID: 17315156; PMCID: PMC2952542.
      Citations: 60     Fields:    Translation:Humans
    723. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 Mar 01; 109(5):899-906. PMID: 17236224.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    724. Atallah E, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Curr Opin Hematol. 2007 Mar; 14(2):138-44. PMID: 17255791.
      Citations: 1     Fields:    Translation:Humans
    725. Heidel F, Cortes J, Aulitzky W, Letvak L, Kindler T, Huber C, Kantarjian H, Fischer T, R?cker FG, D?hner H. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer. 2007 Mar 01; 109(5):907-14. PMID: 17285599.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    726. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar; 16(3):381-92. PMID: 17302532.
      Citations: 3     Fields:    Translation:HumansAnimals
    727. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol. 2007 Mar; 136(6):800-5. PMID: 17341265.
      Citations: 23     Fields:    Translation:Humans
    728. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 2:S51-7. PMID: 17382013.
      Citations:    Fields:    Translation:Humans
    729. Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 3:S105-12. PMID: 17382019.
      Citations: 6     Fields:    Translation:Humans
    730. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007 Feb 15; 109(4):713-7. PMID: 17219444.
      Citations: 47     Fields:    Translation:Humans
    731. Kantarjian HM, Giles F, Cortes J, Quint?s-Cardama A. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2007 Feb 15; 13(4):1089-97. PMID: 17317816.
      Citations: 27     Fields:    Translation:Humans
    732. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85. PMID: 17299097.
      Citations: 119     Fields:    Translation:Humans
    733. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J, Quint?s-Cardama A. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007 Feb; 48(2):283-9. PMID: 17325887.
      Citations: 8     Fields:    Translation:Humans
    734. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7. PMID: 17223919.
      Citations: 90     Fields:    Translation:Humans
    735. Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O'Brien S, Giles F, Albitar M. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica. 2007 Feb; 92(2):170-5. PMID: 17296565.
      Citations: 6     Fields:    Translation:HumansCells
    736. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73. PMID: 17133405.
      Citations: 43     Fields:    Translation:HumansCells
    737. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J, Quint?s-Cardama A. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55. PMID: 17154172.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    738. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31. PMID: 17292738.
      Citations: 7     Fields:    Translation:Humans
    739. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007; 25(6):481-96. PMID: 17523753.
      Citations: 80     Fields:    Translation:Humans
    740. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S4-14. PMID: 17292736.
      Citations: 12     Fields:    Translation:Humans
    741. Atallah E, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007 Jan; 13(1):14; author reply 15-6. PMID: 17206119.
      Citations: 8     Fields:    Translation:Humans
    742. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15; 109(8):3207-13. PMID: 17185463.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    743. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006 Dec 19; 145(12):913-23. PMID: 17179059.
      Citations: 73     Fields:    Translation:Humans
    744. Kantarjian H, Cortes J, Quint?s-Cardama A. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. Future Oncol. 2006 Dec; 2(6):655-65. PMID: 17155893.
      Citations: 5     Fields:    Translation:Humans
    745. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2006 Nov; 18(6):578-83. PMID: 16988578.
      Citations: 4     Fields:    Translation:Humans
    746. Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006 Oct 15; 107(8):1918-29. PMID: 16986126.
      Citations: 45     Fields:    Translation:HumansCells
    747. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9. PMID: 16955510.
      Citations: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    748. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006 Oct 01; 107(7):1429-39. PMID: 16948123.
      Citations: 12     Fields:    Translation:Humans
    749. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007 Jan 15; 109(2):497-9. PMID: 16990591.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    750. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007 Jan 15; 109(2):500-2. PMID: 16990603.
      Citations: 93     Fields:    Translation:HumansCells
    751. Arana-Yi C, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H, Verstovsek S, Quint?s-Cardama A. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist. 2006 Sep; 11(8):929-43. PMID: 16951397.
      Citations: 5     Fields:    Translation:Humans
    752. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006 Sep; 81(9):1241-57. PMID: 16970222.
      Citations: 99     Fields:    Translation:HumansCells
    753. Pan J, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S, Quint?s-Cardama A. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007 Jan 01; 109(1):315-22. PMID: 16912224.
      Citations: 23     Fields:    Translation:HumansCells
    754. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7. PMID: 16882708.
      Citations: 243     Fields:    Translation:HumansCells
    755. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711; PMCID: PMC1895437.
      Citations: 180     Fields:    Translation:HumansCellsCTClinical Trials
    756. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35. PMID: 16899611.
      Citations: 121     Fields:    Translation:HumansCTClinical Trials
    757. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73. PMID: 16855631.
      Citations: 120     Fields:    Translation:HumansCells
    758. Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):393-4. PMID: 16845427.
      Citations: 5     Fields:    Translation:Humans
    759. Cortes JE, Quint?s-Cardama A. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006 Jul; 81(7):973-88. PMID: 16835977.
      Citations: 51     Fields:    Translation:Humans
    760. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006 Oct 15; 108(8):2811-3. PMID: 16809614.
      Citations: 38     Fields:    Translation:Humans
    761. Verstovsek S, Akin C, Manshouri T, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H, Quint?s-Cardama A. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006 Nov; 30(11):1365-70. PMID: 16797704.
      Citations: 18     Fields:    Translation:HumansCells
    762. Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H, Verstovsek S, Quint?s-Cardama A. A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome. Leukemia. 2006 Sep; 20(9):1638-40. PMID: 16791272.
      Citations:    Fields:    Translation:Humans
    763. Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O'Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006 Aug; 134(3):341-3. PMID: 16787500.
      Citations: 2     Fields:    Translation:Humans
    764. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51. PMID: 16688777.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    765. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15; 354(24):2531-41. PMID: 16775234.
      Citations: 553     Fields:    Translation:HumansCTClinical Trials
    766. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51. PMID: 16775235.
      Citations: 382     Fields:    Translation:HumansCTClinical Trials
    767. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006 Sep 15; 108(6):1835-40. PMID: 16709931.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    768. Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet, Baccarani M, Guilhot F. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20. PMID: 16709930.
      Citations: 308     Fields:    Translation:HumansCells
    769. Verstovsek S, Giles FJ, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H, Quint?s-Cardama A. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006 Dec; 30(12):1499-505. PMID: 16682077.
      Citations: 13     Fields:    Translation:HumansCells
    770. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503. PMID: 16675707.
      Citations: 116     Fields:    Translation:Humans
    771. Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May; 83(4):289-93. PMID: 16757426.
      Citations: 9     Fields:    Translation:Humans
    772. Cortes J, Quint?s-Cardama A. Kinase inhibitors in chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2006 May; 4(5):365-74. PMID: 16728945.
      Citations: 2     Fields:    Translation:HumansCells
    773. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84. PMID: 16583431.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    774. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer. 2006 Apr 15; 106(8):1730-8. PMID: 16532439.
      Citations: 12     Fields:    Translation:HumansCells
    775. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64. PMID: 16609064.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    776. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3. PMID: 16601247.
      Citations: 29     Fields:    Translation:Humans
    777. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80. PMID: 16502413.
      Citations: 156     Fields:    Translation:HumansCTClinical Trials
    778. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15. PMID: 16463391.
      Citations: 25     Fields:    Translation:Humans
    779. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM, Hehlmann R. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37. PMID: 16522812; PMCID: PMC1895821.
      Citations: 322     Fields:    Translation:HumansCells
    780. Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006 Mar 01; 106(5):1099-109. PMID: 16435387.
      Citations: 26     Fields:    Translation:Humans
    781. Cortes J. Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol. 2006 Mar; 13(2):79-86. PMID: 16456373.
      Citations: 2     Fields:    Translation:HumansAnimals
    782. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8. PMID: 16435386.
      Citations: 203     Fields:    Translation:Humans
    783. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22. PMID: 16478631.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    784. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006 Mar 01; 24(7):1204-8. PMID: 16446320.
      Citations: 53     Fields:    Translation:HumansCells
    785. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52. PMID: 16342165.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    786. Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15; 106(2):337-45. PMID: 16353201.
      Citations: 16     Fields:    Translation:Humans
    787. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51. PMID: 16403905.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    788. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006 Jan; 50(1):143-7. PMID: 16377679; PMCID: PMC1346781.
      Citations: 44     Fields:    Translation:Humans
    789. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006 Jan 01; 106(1):120-7. PMID: 16331634.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    790. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24. PMID: 16293603; PMCID: PMC1895741.
      Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
    791. Giles FJ, Cortes JE, Kantarjian HM. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med. 2005 Nov; 5(7):615-23. PMID: 16305488.
      Citations: 10     Fields:    Translation:Humans
    792. Merzianu M, Medeiros LJ, Cortes J, Yin C, Lin P, Jones D, Glassman A, Kantarjian H, Huh Y. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol. 2005 Nov; 124(5):807-14. PMID: 16203287.
      Citations: 10     Fields:    Translation:HumansCells
    793. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24. PMID: 16278404.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    794. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9. PMID: 16354329.
      Citations: 12     Fields:    Translation:HumansCells
    795. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2. PMID: 16195326.
      Citations: 17     Fields:    Translation:Humans
    796. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6. PMID: 16078266.
      Citations: 14     Fields:    Translation:HumansCells
    797. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24. PMID: 16166440.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    798. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6316-24. PMID: 16155014.
      Citations: 2     Fields:    Translation:Humans
    799. Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res. 2005 Sep 01; 11(17):6247-55. PMID: 16144928.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    800. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4. PMID: 16123215.
      Citations: 23     Fields:    Translation:HumansCells
    801. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer. 2005 Aug 15; 104(4):777-80. PMID: 15971197.
      Citations: 1     Fields:    Translation:Humans
    802. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54. PMID: 15973664.
      Citations: 23     Fields:    Translation:Humans
    803. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
      Citations: 4     Fields:    Translation:Humans
    804. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M, Mestan J. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7. PMID: 16000593.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    805. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma. 2005 Jul; 46(7):993-7. PMID: 16019549.
      Citations: 4     Fields:    Translation:Humans
    806. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7. PMID: 15861412.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    807. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005 May 15; 103(10):2099-108. PMID: 15830345.
      Citations: 25     Fields:    Translation:Humans
    808. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56. PMID: 15883410.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    809. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 01; 11(9):3425-32. PMID: 15867244.
      Citations: 93     Fields:    Translation:HumansCTClinical Trials
    810. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. PMID: 15863204.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    811. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8. PMID: 15767647.
      Citations: 131     Fields:    Translation:Humans
    812. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88. PMID: 15767648.
      Citations: 264     Fields:    Translation:HumansCTClinical Trials
    813. Tefferi A, Dewald GW, Litzow ML, Cortes J, Mauro MJ, Talpaz M, Kantarjian HM. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005 Mar; 80(3):390-402. PMID: 15757021.
      Citations: 6     Fields:    Translation:HumansCells
    814. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005 Apr 20; 23(12):2805-12. PMID: 15728224.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    815. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7. PMID: 15659618.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    816. Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005 Jan; 16(1):139-45. PMID: 15598951.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    817. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15; 101(12):2788-801. PMID: 15481055.
      Citations: 176     Fields:    Translation:HumansCTClinical Trials
    818. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6. PMID: 15572595.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    819. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95. PMID: 15512806.
      Citations: 5     Fields:    Translation:HumansCells
    820. Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol. 2004 Nov; 77(3):209-14. PMID: 15495258.
      Citations: 9     Fields:    Translation:Humans
    821. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7. PMID: 15486072.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    822. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004 Oct 01; 104(7):2204-5. PMID: 15377577.
      Citations: 79     Fields:    Translation:Humans
    823. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008. PMID: 15329909.
      Citations: 25     Fields:    Translation:HumansCells
    824. Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer. 2004 Jul 15; 101(2):332-6. PMID: 15241831.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    825. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004 Jun 15; 100(12):2592-7. PMID: 15197801.
      Citations: 11     Fields:    Translation:Humans
    826. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88. PMID: 15198956.
      Citations: 31     Fields:    Translation:HumansCells
    827. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15; 104(6):1624-30. PMID: 15178574.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    828. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60. PMID: 15120945.
      Citations: 4     Fields:    Translation:Humans
    829. Borthakur G, Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004 Jun; 79(5):411-9. PMID: 15239390.
      Citations: 7     Fields:    Translation:Humans
    830. Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):569-84, viii. PMID: 15271393.
      Citations: 27     Fields:    Translation:Humans
    831. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):753-74, xii. PMID: 15271404.
      Citations: 12     Fields:    Translation:HumansCells
    832. Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):619-39, ix. PMID: 15271396.
      Citations: 1     Fields:    Translation:HumansCells
    833. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):671-84, x. PMID: 15271399.
      Citations: 25     Fields:    Translation:HumansCells
    834. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res. 2004 Jun; 28(6):613-8. PMID: 15120938.
      Citations: 3     Fields:    Translation:Humans
    835. Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, Talpaz M, Kantarjian H. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004 Jun 01; 100(11):2396-402. PMID: 15160343.
      Citations: 9     Fields:    Translation:Humans
    836. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004 May 15; 10(10):3371-6. PMID: 15161691.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    837. Cortes J, Kantarjian H. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer. 2004 May 15; 100(10):2064-78. PMID: 15139047.
      Citations: 5     Fields:    Translation:HumansCells
    838. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM, Cox JD. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer. 2004 May 15; 100(10):2176-80. PMID: 15139061.
      Citations: 12     Fields:    Translation:Humans
    839. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004 May 01; 10(9):2908-17. PMID: 15131024.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    840. Cortes J. Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome. Curr Hematol Rep. 2004 May; 3(3):157-8. PMID: 15087061.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    841. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 01; 104(3):865-72. PMID: 15090449.
      Citations: 95     Fields:    Translation:Humans
    842. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92. PMID: 15051776.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    843. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58. PMID: 15042679.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    844. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95. PMID: 15059141.
      Citations: 31     Fields:    Translation:HumansCells
    845. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res. 2004 Apr; 28(4):353-7. PMID: 15109534.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    846. Giles FJ, Kantarjian H, Cortes J. Novel therapies for patients with chronic myeloid leukemia. Expert Rev Anticancer Ther. 2004 Apr; 4(2):271-82. PMID: 15056057.
      Citations:    Fields:    Translation:HumansAnimalsCells
    847. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8. PMID: 15109537.
      Citations: 6     Fields:    Translation:Humans
    848. Kantarjian H, Cortes J. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia. 2004 Mar; 18(3):650. PMID: 14737079.
      Citations: 1     Fields:    Translation:Humans
    849. Orsolic N, Giles FJ, Gourdeau H, Golemovic M, Beran M, Cortes J, Freireich EJ, Kantarjian H, Verstovsek S. Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br J Haematol. 2004 Mar; 124(6):727-38. PMID: 15009060.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    850. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):568-73. PMID: 14745874.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    851. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004 Feb 01; 100(3):441-54. PMID: 14745859.
      Citations: 9     Fields:    Translation:Humans
    852. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004 Jan 01; 100(1):116-21. PMID: 14692031.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    853. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75. PMID: 14734453.
      Citations: 12     Fields:    Translation:Humans
    854. Ravandi F, Cortes J. Investigational agents in myeloid disorders. Adv Pharmacol. 2004; 51:59-97. PMID: 15464905.
      Citations:    Fields:    Translation:HumansCells
    855. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004 Apr 15; 103(8):2873-8. PMID: 15070658.
      Citations: 91     Fields:    Translation:HumansCells
    856. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63. PMID: 14669286.
      Citations: 41     Fields:    Translation:HumansCellsCTClinical Trials
    857. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003 Dec 15; 98(12):2636-42. PMID: 14669283.
      Citations: 18     Fields:    Translation:HumansCells
    858. Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res. 2003 Dec; 27(12):1091-6. PMID: 12921945.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    859. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 01; 98(11):2483-7. PMID: 14635084.
      Citations: 20     Fields:    Translation:HumansCells
    860. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83. PMID: 12921943.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    861. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004 Mar 01; 103(5):1635-40. PMID: 14604977.
      Citations: 270     Fields:    Translation:HumansCellsCTClinical Trials
    862. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, O'Brien S, Albitar M, Kantarjian H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2003 Nov; 123(3):436-41. PMID: 14617002.
      Citations: 8     Fields:    Translation:Humans
    863. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003 Nov 01; 98(9):1905-11. PMID: 14584073.
      Citations: 30     Fields:    Translation:Humans
    864. Drummond MW, Holyoake TL. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Oct 15; 98(8):1776-7; author reply 1777-8. PMID: 14534900.
      Citations:    Fields:    Translation:Humans
    865. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407. PMID: 14551133.
      Citations: 172     Fields:    Translation:HumansCTClinical Trials
    866. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7. PMID: 12860008.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    867. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7. PMID: 14508830.
      Citations: 4     Fields:    Translation:HumansCells
    868. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003 Oct 01; 102(7):2702-3; author reply 2703-4. PMID: 14504074.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    869. Cortes J, Giles F. New agents in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2003 Oct; 1(4):501-12. PMID: 19774741.
      Citations:    Fields:    Translation:HumansPHPublic Health
    870. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003 Oct; 27(10):887-91. PMID: 12860007.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    871. Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F, Estey E, Kantarjian HM. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res. 2003 Sep 15; 9(11):4084-91. PMID: 14519630.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    872. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Sep 15; 98(6):1105-13. PMID: 12973833.
      Citations: 23     Fields:    Translation:Humans
    873. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52. PMID: 13680159.
      Citations: 4     Fields:    Translation:Humans
    874. Giles FJ, Cortes JE, Halliburton TA, Mallard SJ, Estey EH, Waddelow TA, Lim JT. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003 Sep; 37(9):1182-5. PMID: 12921496.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    875. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003 Sep 01; 98(5):888-93. PMID: 12942553.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    876. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 Dec 15; 102(13):4527-34. PMID: 12947010.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    877. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8. PMID: 12910522.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    878. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003 Aug; 88(8):853-63. PMID: 12935973.
      Citations: 19     Fields:    Translation:HumansCells
    879. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003 Aug; 4 Suppl 1:S30-5. PMID: 14556673.
      Citations: 5     Fields:    Translation:Humans
    880. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 01; 98(3):522-8. PMID: 12879469.
      Citations: 61     Fields:    Translation:Humans
    881. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003 Aug 01; 98(3):437-57. PMID: 12879460.
      Citations: 22     Fields:    Translation:Humans
    882. Estey EH, Thall PF, Wang X, Verstovsek S, Cortes J, Kantarjian HM. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood. 2003 Nov 01; 102(9):3097-9. PMID: 12842982.
      Citations: 5     Fields:    Translation:HumansCells
    883. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003 Jul 01; 98(1):81-5. PMID: 12833459.
      Citations: 13     Fields:    Translation:Humans
    884. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica. 2003 Jul; 88(7):733-6. PMID: 12857550.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    885. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 2003 Jul; 27(7):661-9. PMID: 12681367.
      Citations: 3     Fields:    Translation:Humans
    886. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 01; 102(12):3906-11. PMID: 12816862.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    887. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer. 2003 Jun 15; 97(12):3010-6. PMID: 12784336.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    888. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86. PMID: 12791647.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    889. Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep; 52(3):223-8. PMID: 12783199.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    890. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003 Jun 01; 97(11):2760-6. PMID: 12767088.
      Citations: 19     Fields:    Translation:Humans
    891. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res. 2003 Jun; 27(6):475-9. PMID: 12648505.
      Citations:    Fields:    Translation:HumansCells
    892. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. PMID: 12783207.
      Citations: 1     Fields:    Translation:Humans
    893. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8. PMID: 12712475.
      Citations: 4     Fields:    Translation:Humans
    894. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8. PMID: 12730116.
      Citations: 8     Fields:    Translation:HumansCells
    895. Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85. PMID: 12752098.
      Citations: 6     Fields:    Translation:Humans
    896. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer. 2003 May 01; 97(9):2218-24. PMID: 12712474.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    897. Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer. 2003 May 01; 97(9):2212-7. PMID: 12712473.
      Citations: 10     Fields:    Translation:Humans
    898. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7. PMID: 12721247.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    899. Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003 May; 2(3):202-8. PMID: 12901341.
      Citations: 3     Fields:    Translation:Humans
    900. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20. PMID: 12655528.
      Citations: 35     Fields:    Translation:Humans
    901. Leopold LH, Berger MS, Cheng SC, Cortes-Franco JE, Giles FJ, Estey EH. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol. 2003 Apr; 1(4):220-5. PMID: 16224410.
      Citations: 5     Fields:    Translation:Humans
    902. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res. 2003 Apr; 27(4):301-4. PMID: 12531220.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    903. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14. PMID: 12660384.
      Citations: 399     Fields:    Translation:HumansCells
    904. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. PMID: 12649163.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    905. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6. PMID: 12637470.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    906. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7. PMID: 12627513.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    907. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73. PMID: 12637486.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    908. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003 Jul 01; 102(1):83-6. PMID: 12637317.
      Citations: 43     Fields:    Translation:Humans
    909. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M, Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer. 2003 Mar 01; 97(5):1248-52. PMID: 12599232.
      Citations: 1     Fields:    Translation:Humans
    910. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 01; 97(5):1234-41. PMID: 12599230.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    911. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003 Mar; 9(3):976-80. PMID: 12631595.
      Citations: 30     Fields:    Translation:HumansCells
    912. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15; 101(12):4714-6. PMID: 12595304.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    913. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003 Feb 15; 97(4):1033-41. PMID: 12569603.
      Citations: 59     Fields:    Translation:HumansCells
    914. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15; 101(10):3794-800. PMID: 12560227.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    915. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003 Jan 15; 97(2):450-6. PMID: 12518369.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    916. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5. PMID: 12522009.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    917. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003 Jan; 9(1):160-6. PMID: 12538464.
      Citations: 14     Fields:    Translation:Humans
    918. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003 Jan; 40(1):79-86. PMID: 12563614.
      Citations: 16     Fields:    Translation:Humans
    919. Thomas DA, Cortes J, Kantarjian HM. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol. 2002 Dec; 15(4):771-90. PMID: 12617876.
      Citations: 2     Fields:    Translation:Humans
    920. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6. PMID: 12497210.
      Citations: 11     Fields:    Translation:Humans
    921. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):87-90. PMID: 12497211.
      Citations: 8     Fields:    Translation:Humans
    922. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002 Dec; 50(6):497-500. PMID: 12451477.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    923. Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol. 2002 Oct; 39(4 Suppl 3):20-4. PMID: 12447848.
      Citations: 7     Fields:    Translation:HumansAnimals
    924. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002 Oct; 118(4):560-6. PMID: 12375643.
      Citations: 36     Fields:    Translation:HumansCells
    925. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002 Oct; 87(10):1114-6. PMID: 12368170.
      Citations: 1     Fields:    Translation:Humans
    926. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003 Jan 15; 101(2):473-5. PMID: 12393385.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    927. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002 Sep 01; 100(5):1590-5. PMID: 12176876.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    928. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T, Estey E, EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center, Fi?re D. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002 Sep; 16(9):1615-21. PMID: 12200672.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    929. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002 Sep; 26(9):881-4. PMID: 12127565.
      Citations: 22     Fields:    Translation:Humans
    930. Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002 Aug; 87(8):804-7. PMID: 12161355.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    931. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul; 8(7):2167-76. PMID: 12114417.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    932. Cortes JE, Kurzrock R, Kantarjian HM. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):26-30. PMID: 12214290.
      Citations:    Fields:    Translation:Humans
    933. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9. PMID: 12008081.
      Citations: 19     Fields:    Translation:HumansCells
    934. Verstovsek S, Estey E, Manshouri T, Giles FJ, Cortes J, Beran M, Rogers A, Keating M, Kantarjian H, Albitar M. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002 Jul; 118(1):151-6. PMID: 12100142.
      Citations: 12     Fields:    Translation:Humans
    935. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87. PMID: 12114418.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    936. Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):36-8. PMID: 12214292.
      Citations:    Fields:    Translation:Humans
    937. Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul; 8(7):2134-41. PMID: 12114413.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    938. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002 Jun 15; 99(12):4343-9. PMID: 12036860.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    939. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002 Jun 01; 99(11):4222-4. PMID: 12010830.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    940. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002 May 15; 99(10):3547-53. PMID: 11986206.
      Citations: 56     Fields:    Translation:HumansCellsCTClinical Trials
    941. Dabaja BS, Ha CS, Thomas DA, Wilder RB, Gopal R, Cortes J, Bueso-Ramos C, Hess MA, Cox JD, Kantarjian HM. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002 May 15; 94(10):2738-44. PMID: 12173345.
      Citations: 11     Fields:    Translation:Humans
    942. Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002 May 01; 94(9):2416-25. PMID: 12015767.
      Citations: 14     Fields:    Translation:HumansCells
    943. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. PMID: 12153163.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    944. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32. PMID: 11932905.
      Citations: 11     Fields:    Translation:Humans
    945. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002 Mar 15; 99(6):2265-7. PMID: 11877311.
      Citations: 18     Fields:    Translation:Humans
    946. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002 Mar 01; 94(5):1492-9. PMID: 11920506.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    947. Verstovsek S, Kantarjian H, Manshouri T, O'Brien S, Faderl S, Talpaz M, Cortes J, Albitar M. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer. 2002 Mar 01; 94(5):1517-21. PMID: 11920509.
      Citations: 6     Fields:    Translation:Humans
    948. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002 Feb 01; 94(3):773-9. PMID: 11857312.
      Citations: 29     Fields:    Translation:Humans
    949. Hui YF, Giles FJ, Cortes JE. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents. Invest New Drugs. 2002 Feb; 20(1):49-53. PMID: 12003194.
      Citations: 5     Fields:    Translation:Humans
    950. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2002; 111-35. PMID: 12446421.
      Citations: 25     Fields:    Translation:Humans
    951. Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, Cortes J, Giles FJ, O'Brien S. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001 Nov 15; 92(10):2501-7. PMID: 11745182.
      Citations: 3     Fields:    Translation:Humans
    952. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001 Nov 01; 19(21):4165-72. PMID: 11689585.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    953. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 2001 Oct 15; 92(8):1999-2015. PMID: 11596013.
      Citations: 25     Fields:    Translation:Humans
    954. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, Kantarjian HM. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001 Sep 15; 98(6):1708-13. PMID: 11535501.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    955. Smith JA, Cortes J, Newman RA, Madden TL. Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasma. J Chromatogr B Biomed Sci Appl. 2001 Sep 05; 760(2):247-53. PMID: 11530983.
      Citations: 2     Fields:    Translation:Humans
    956. Estey E, Koller C, Cortes J, Reed P, Freireich E, Giles F, Kantarjian H. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leuk Lymphoma. 2001 Jul; 42(3):309-16. PMID: 11699395.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    957. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001 Jul 01; 92(1):7-14. PMID: 11443603.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    958. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72. PMID: 11391574.
      Citations: 8     Fields:    Translation:Humans
    959. Ravandi F, Hayes K, Cortes J, Albitar M, Glassman A, Talpaz M, Kantarjian HM. Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia. Cancer. 2001 May 01; 91(9):1704-8. PMID: 11335894.
      Citations: 2     Fields:    Translation:HumansCells
    960. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70. PMID: 11304768.
      Citations: 125     Fields:    Translation:HumansCTClinical Trials
    961. Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma. 2001 Apr; 41(3-4):309-19. PMID: 11378543.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    962. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20. PMID: 11230486.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    963. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001 Feb; 40(5-6):511-20. PMID: 11426524.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    964. Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001 Feb; 15(1):145-62. PMID: 11253605.
      Citations: 20     Fields:    Translation:Humans
    965. Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM. Antiangiogenic therapy in leukemia. Acta Haematol. 2001; 106(4):190-207. PMID: 11815717.
      Citations: 3     Fields:    Translation:Humans
    966. Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs. 2001; 19(1):13-20. PMID: 11291829.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    967. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82. PMID: 11064355.
      Citations: 34     Fields:    Translation:Humans
    968. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000 Oct 15; 18(20):3513-21. PMID: 11032593.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    969. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9. PMID: 10778970.
      Citations: 16     Fields:    Translation:HumansCells
    970. Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles FJ, Pierce S, Albitar M. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000 Feb 01; 88(3):570-6. PMID: 10649249.
      Citations:    Fields:    Translation:HumansCells
    971. Cortes J, Kantarjian HM. Promising approaches in acute leukemia. Invest New Drugs. 2000 Feb; 18(1):57-82. PMID: 10830141.
      Citations:    Fields:    Translation:HumansAnimals
    972. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000 Feb; 18(3):547-61. PMID: 10653870.
      Citations: 213     Fields:    Translation:HumansCTClinical Trials
    973. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma. 2000 Feb; 36(5-6):479-84. PMID: 10784392.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    974. Ravandi-Kashani F, Cortes J, Giles FJ. Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome. Leuk Lymphoma. 2000 Feb; 36(5-6):631-7. PMID: 10784409.
      Citations: 5     Fields:    Translation:Humans
    975. Rodriguez J, Cortes J, Talpaz M, O'Brien S, Smith TL, Rios MB, Kantarjian H. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000 Jan; 6(1):147-52. PMID: 10656443.
      Citations: 4     Fields:    Translation:Humans
    976. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000 Jan; 36(3-4):263-73. PMID: 10674898.
      Citations: 32     Fields:    Translation:HumansCells
    977. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999 Dec 15; 86(12):2632-41. PMID: 10594858.
      Citations: 21     Fields:    Translation:Humans
    978. Ravandi F, Cortes J, Albitar M, Arlinghaus R, Qiang Guo J, Talpaz M, Kantarjian HM. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999 Dec; 107(3):581-6. PMID: 10583263.
      Citations: 11     Fields:    Translation:Humans
    979. Kantarjian HM, Talpaz M, O'Brien S, Manshouri T, Cortes J, Giles F, Rios MB, Croce CM, Albitar M. Significance of FHIT expression in chronic myelogenous leukemia. Clin Cancer Res. 1999 Dec; 5(12):4059-64. PMID: 10632340.
      Citations: 2     Fields:    Translation:HumansCells
    980. Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma. 1999 Nov; 35(5-6):483-9. PMID: 10609785.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    981. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999 Oct 01; 94(7):2230-5. PMID: 10498593.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    982. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999 Oct 01; 86(7):1203-9. PMID: 10506705.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    983. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 Oct 01; 86(7):1216-30. PMID: 10506707.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    984. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999 Sep; 5(3):159-63. PMID: 10641574.
      Citations: 4     Fields:    Translation:HumansCells
    985. Giles FJ, Kantarjian HM, Cortes J, Thomas DA, Talpaz M, Manshouri T, Albitar M. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer. 1999 Sep 01; 86(5):805-13. PMID: 10463979.
      Citations: 9     Fields:    Translation:Humans
    986. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A, Kantarjian H. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma. 1999 Sep; 35(1-2):109-18. PMID: 10512168.
      Citations: 4     Fields:    Translation:Humans
    987. Cortes J, Fayad L, O'Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res. 1999 Sep; 5(9):2491-7. PMID: 10499624.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    988. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999 Sep; 17(9):2819-30. PMID: 10561358.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    989. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 Aug; 17(8):2461-70. PMID: 10561310.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    990. Faderl S, Kantarjian HM, Manshouri T, Chan CY, Pierce S, Hays KJ, Cortes J, Thomas D, Estrov Z, Albitar M. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61. PMID: 10430092.
      Citations: 5     Fields:    Translation:HumansCells
    991. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer. 1999 Jun 15; 85(12):2583-8. PMID: 10375106.
      Citations: 9     Fields:    Translation:Humans
    992. Ravandi-Kashani F, Estey E, Cortes J, Medeiros LJ, Giles FJ. Granulocytic sarcoma of the pancreas: a report of two cases and literature review. Clin Lab Haematol. 1999 Jun; 21(3):219-24. PMID: 10448606.
      Citations: 11     Fields:    Translation:Humans
    993. Dabaja BS, Faderl S, Thomas D, Cortes J, O'Brien S, Nasr F, Pierce S, Hayes K, Glassman A, Keating M, Kantarjian HM. Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia. 1999 Jun; 13(6):869-72. PMID: 10360374.
      Citations: 2     Fields:    Translation:HumansCells
    994. Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol. 1999 May; 10(5):577-83. PMID: 10416008.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    995. Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood. 1999 May 01; 93(9):3149-50. PMID: 10336269.
      Citations:    Fields:    Translation:Humans
    996. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84. PMID: 10194425.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    997. Issa JP, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, Talpaz M. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999 Mar 15; 93(6):2075-80. PMID: 10068681.
      Citations: 9     Fields:    Translation:HumansCells
    998. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999 Jan; 17(1):284-92. PMID: 10458244.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    999. Vey N, Kantarjian H, Beran M, O'Brien S, Cortes J, Koller C, Estey E. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. Invest New Drugs. 1999; 17(1):89-95. PMID: 10555127.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    1000. Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs. 1999; 17(1):81-7. PMID: 10555126.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    1001. Rodriguez J, Cortes J, Smith T, O'Brien S, Rios MB, Talpaz M, Kantarjian H. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 1998 Dec; 16(12):3782-7. PMID: 9850022.
      Citations: 3     Fields:    Translation:Humans
    1002. Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M, Freireich EJ, Kantarjian H. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998 Oct; 16(10):3279-85. PMID: 9779702.
      Citations: 7     Fields:    Translation:Humans
    1003. Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia. 1998 Jun; 12(6):860-4. PMID: 9639411.
      Citations: 10     Fields:    Translation:HumansCells
    1004. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia. 1998 Apr; 12(4):455-62. PMID: 9557601.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    1005. Bseiso AW, Kantarjian HM, Guo JQ, Cortes J, Talpaz M, Koller C, AlBitar M, Keating M, Arlinghaus R. Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. Leukemia. 1997 Sep; 11(9):1583-7. PMID: 9305617.
      Citations:    Fields:    Translation:Humans
    1006. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma. 1997 Jul; 26(3-4):251-9. PMID: 9322887.
      Citations: 19     Fields:    Translation:HumansAnimals
    1007. Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, Keating M, Talpaz M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 1997 Jul; 11(7):929-32. PMID: 9204970.
      Citations: 2     Fields:    Translation:Humans
    1008. Cortes J, Kantarjian HM, Giralt S, Talpaz M. Natural history and staging of chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997 Jun; 10(2):277-90. PMID: 9376664.
      Citations: 4     Fields:    Translation:Humans
    1009. Cortes J, Kantarjian H, Talpaz M, O'Brien S, Beran M, Koller C, Keating M. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia. 1997 Jun; 11(6):788-91. PMID: 9177428.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    1010. Sacchi S, Cortes J, Kantarjian H, Talpaz M. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia. Hematopathol Mol Hematol. 1997-1998; 11(1):41-7. PMID: 9439979.
      Citations:    Fields:    Translation:HumansCells
    1011. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med. 1996 Apr; 100(4):452-5. PMID: 8610733.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    1012. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996 Mar; 21(1-2):85-92. PMID: 8907274.
      Citations: 7     Fields:    Translation:Humans
    1013. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995 Sep 15; 86(6):2091-7. PMID: 7662956.
      Citations: 37     Fields:    Translation:Humans
    1014. Ghaddar HB, Cortes J, Salomaa V, Kark JD, Davis CE, Folsom AR, Heiss G, Stinson V, Wu KK. Correlation of specific platelet activation markers with carotid arterial wall thickness. Thromb Haemost. 1995 Sep; 74(3):943-8. PMID: 8571326.
      Citations: 2     Fields:    Translation:Humans
    1015. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995 Feb 15; 85(4):1083-94. PMID: 7849296.
      Citations: 62     Fields:    Translation:HumansCells
    1016. Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia. 1994 Dec; 8(12):2174-8. PMID: 7808007.
      Citations: 7     Fields:    Translation:HumansCells
    1017. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. 1993 Mar; 7(3):378-83. PMID: 8445943.
      Citations: 8     Fields:    Translation:Humans
    1018. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Journal of Clinical Oncology. 34:1864-1871.
    1019. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients with CML-CP. Clinical Lymphoma, Myeloma and Leukemia. 16:286-296.
    1020. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    1021. Crenolanib is a potent inhibitor of flt3 with activity against resistance-Conferring point mutants. Blood. 123:94-100.
    1022. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    1023. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487-30499.
    1024. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leukemia and Lymphoma. 56:1342-1345.
    1025. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia.
    1026. Errata. Blood. 126:1049.
    1027. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer.
    1028. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology.
    1029. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leukemia and Lymphoma. 1-4.
    1030. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:S86-S92.
    1031. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine. 13.
    1032. Chronic myeloid leukemia. Haematologica. 101:541-558.
    1033. Chemotherapy-induced palmar plantar erythrodysesthesia syndrome (ppes) recall following different chemotherapy regimens in patients with leukemia. Blood. 96.
    1034. Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML. Cancer Biology and Therapy. 5:711.
    1035. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). American Journal of Hematology. 91:227-232.
    1036. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer genetics. 208:571-574.
    1037. A two-stage approach for dynamic prediction of time-to-event distributions. Statistics in Medicine.
    1038. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leukemia and Lymphoma. 1-11.
    1039. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.
    1040. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.
    1041. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
    1042. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology. 172:97-110.
    1043. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma. 56:2092-2097.
    1044. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia.
    1045. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma. 55:1451-1462.
    1046. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
    1047. Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clinical Lymphoma, Myeloma and Leukemia. 15:433-438.
    1048. Erratum. Nature Reviews Drug Discovery. 10:318.
    1049. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry Part A. 87:346-356.
    1050. New drugs in acute myeloid leukemia. Annals of Oncology. 27:770-778.
    1051. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies. Journal for ImmunoTherapy of Cancer. 4.
    1052. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology.
    1053. Chronic Myelogenous Leukemia. 76-88.
    1054. Chronic Myeloid Leukemia. 1944-1957.e2.
    1055. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia.
    1056. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience. Leukemia and Lymphoma. 57:237-239.
    1057. Erratum. Cancer. 106:1641.
    1058. First-line treatment for patients with CML in chronic phase. ONCOLOGY (United States). 27.
    1059. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. The Lancet Haematology. 2:e12-e20.
    1060. Planned pregnancy for a patient with chronic myeloid leukemia. Internet Journal of Oncology. 7.
    1061. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer.
    1062. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    1063. ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia. American Journal of Hematology. 85:277-280.
    1064. Acute myeloid leukemia. Expert Review of Hematology. 1-13.
    1065. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    1066. Blood. 96.
    1067. Erratum. British Journal of Haematology. 108:461.
    1068. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology. 171:471-477.
    1069. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leukemia and Lymphoma.
    1070. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer.
    1071. Prognostic significance of serum beta-2 microglobulin in myelodisplastic syndromes. Blood. 96.
    1072. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies. The Lancet Haematology. 2:e339-e346.
    1073. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR). The Lancet Haematology. 3:e581-e591.
    1074. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Current Medical Research and Opinion. 1-9.
    1075. American Journal of Hematology. 92:E3-E4.
    1076. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
    1077. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.
    1078. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies. Leukemia Research. 50:123-131.
    1079. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia. Cancer.
    1080. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742-2750.
    1081. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.
    1082. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica. 101:e324-e327.
    1083. Leukemia in the elderly. Cancer Bulletin. 47:203-211.
    1084. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma. 56:390-394.
    1085. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology.
    1086. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal. 6.
    1087. Comments on the hammersmith policy. Seminars in Hematology. 40:104-113.
    1088. Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase). P and T. 34:97.
    1089. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 127:703-712.
    1090. Myelopathy following intrathecal chemotherapy in adults. Journal of Neuro-Oncology.
    1091. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer.
    1092. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy. 21:663-667.
    1093. New tyrosine kinase inhibitors in chronic myeloid leukemia (CML). Leukemia Research. 31.
    1094. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    1095. The role of craniospinal irradiation (csi) in adults with central nervous system (cns) recurrence of leukemia. Cancer Journal. 9:514-515.
    1096. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100:1058-1063.
    1097. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Frontiers in Oncology. 3 SEP.
    1098. Characterization of UCN-01 specific binding to human α1-acidic-glycoprotein. Clinical Pharmacology and Therapeutics. 69.
    1099. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    1100. Chronic myeloid leukemia. Hematology. 3:263-276.
    1101. Final 5-year study results of DASISION. Journal of Clinical Oncology. 34:2333-2340.
    1102. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:323-334.
    1103. Personalized medicine and targeted therapy of leukemia. 815-844.
    1104. Targeting IL11 receptor in leukemia and lymphoma. Clinical Cancer Research. 21:3041-3051.
    1105. Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Opinion on Orphan Drugs. 1:607-623.
    1106. ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia. American Journal of Hematology. 85:283-286.
    1107. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (Cancer (2009) 115 (551-160)). Cancer. 116:3750.
    1108. Standard Management of Patients with Chronic Myeloid Leukemia. 71-85.
    1109. A guide to the use of interferon-alpha in the management of chronic myelogenous leukaemia. BioDrugs. 14:211-220.
    1110. BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response. Molecular Cancer Therapeutics. 9:772.
    1111. Molecular biology and cytogenetics of chronic myeloid leukemia. 29-44.
    1112. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. Expert Review of Hematology. 9:419-424.
    1113. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma. 1-6.
    1114. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    1115. Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology. 4:103-117.
    1116. In reply [6]. Journal of Clinical Oncology. 24:3813.
    1117. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    1118. Low dose interleukin-11 is well-tolerated and induces platelet responses in myelodysplasia and other bone marrow failure states. Blood. 96.
    1119. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research. 48:1-5.
    1120. Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers. Leukemia Research. 38:91-94.
    1121. The clinical challenge of imatinib resistance in chronic myeloid leukemia. Targeted Oncology. 1:186-196.
    1122. Chronic myeloid leukemia. 139-153.
    1123. Interferon alfa-2b plus low dose cytarabine for the maintenance of remission in acute myeloid leukemia and advanced myelodysplastic syndrome. Blood. 96.
    1124. Nilotinib for the treatment of chronic myeloid leukemia after imatinib failure. American Journal of Hematology/ Oncology. 7.
    1125. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia and Lymphoma. 56:1392-1397.
    1126. Erratum. Clinical Cancer Research. 10:7787.
    1127. The authors reply. New England Journal of Medicine. 370:577.
    1128. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 100:e494-e495.
    1129. Quantile residual life regression with longitudinal biomarker measurements for dynamic prediction. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    1130. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia. 16:616-624.
    1131. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia.
    1132. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia. Journal of Hematology and Oncology. 8.
    1133. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.
    1134. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 100:898-904.
    1135. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology. 5:29-34.
    1136. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia. The Lancet Haematology. 2:e118-e128.
    1137. Erratum. Blood. 124:981.
    1138. TP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.
    1139. Keeping up with rapid change. Current Hematologic Malignancy Reports. 1:1.
    1140. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:358-363.
    1141. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. American Journal of Hematology. 91:606-616.
    1142. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma. 1-4.
    1143. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Design, Development and Therapy. 233-243.
    1144. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI. Journal of Clinical Investigation. 121:1222.
    1145. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia. The Lancet Oncology. 17:612-621.
    1146. Flt3-itd. Clinical (sorafenib/ac220). 233-249.
    1147. Imatinib-induced postoperative periorbital purpura. Dermatology Online Journal. 20.
    1148. Impact of dose intensity of ponatinib on selected adverse events. Leukemia Research. 48:84-91.
    1149. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes. Biology of Blood and Marrow Transplantation.
    1150. Chemotherapy Foundation Symposium XXVI. P and T. 33:714-719.
    1151. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clinical Lymphoma, Myeloma and Leukemia. 16:152-162.
    1152. Myeloid neoplasms after breast cancer. Leukemia and Lymphoma. 56:1012-1019.
    1153. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 122:3336-3343.
    1154. Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models. Clinical Cancer Research. 22:1687-1698.
    1155. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology.
    1156. The impact of dasatinib on pregnancy outcomes. American Journal of Hematology. 90:1111-1115.
    1157. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase. The Lancet Haematology.
    1158. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:139-145.
    1159. Biology of Chronic and Acute Myeloid Leukemia. 371-383.
    1160. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    1161. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib (Blood (2011) 118, 17 (4567-4576)). Blood. 122:2524.
    1162. Prediction of response and survival in patients with chronicphase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Blood Cancer Journal. 5.
    1163. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.
    1164. Farnesyl transferase inhibitors in myeloid disorders. Oncology. 19.
    1165. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 122:238-248.
    1166. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia. 15:556-562.
    1167. Reply to M. Darmon et al. Journal of Clinical Oncology. 29.
    1168. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    1169. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    CORTES's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (1255)
    Explore
    _
    Co-Authors (168)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _